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Abstract

Metastasis is the main cause of death in breast cancer patients; however, there
are currently no treatments available to treat or prevent metastasis. This is in part
because regulators of metastasis are not yet fully understood. Over the past century
researchers began to study metastasis regulators by different hypotheses, such as the
seed and soil hypothesis which focuses on studying the role of cancer cells, the seeds, and
the tissue microenvironment, the soil, in regulating metastasis. Although lots of studies
have focused on the microenvironment of metastatic sites and their roles in regulating
metastasis, limited studies have focused on the role of the primary tumor
microenvironment in regulating metastasis. Thus, investigating the role of the primary
tumor microenvironment will provide more insight on metastatic regulators which may
lead to the development of new therapeutic strategies to treat or prevent metastasis.
The aim of this study is to evaluate the role of primary tumor microenvironment
in regulating metastasis using a triple negative breast cancer mouse model. Mammary
glands contain two distinct microenvironments, soils: epithelium and stroma. Human
breast cancer originates in the epithelial microenvironment of the mammary glands;
however, researchers are using stromal microenvironment to generate mammary tumors
and bypassing the epithelium. Therefore, we first tested if the epithelial
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microenvironment has an effect on tumor progression and/or metastasis when compared
to stromal microenvironment. We chose the widely used 4T1 mouse model and delivered
the 4T1 cells intraductally into the epithelium. Our results show that the primary tumor’s
epithelial microenvironment promotes more aggressive tumors compared to the stromal
microenvironment.
Knowing that mammary glands exhibit left-right differences in epithelial and
stromal gene expression, we next investigated the role of left versus right epithelial
microenvironment in regulating metastasis. Here we show that the right epithelial
microenvironment more effectively supports M2- like macrophage polarization which
promotes more aggressive 4T1 cells and increased metastatic behavior. Furthermore, we
tested if the left and right mammary tumor microenvironments have differences in
therapeutic response against Emodin, a Chinese herb that targets M2- like macrophage
polarization. Emodin treatment more effectively reduces metastasis in the right tumor
group, while emodin treatment has no effect on the left tumor group. Taken together,
our data indicates for the first time that the left and right mammary tumor
microenvironments are different in metastatic support and therapeutic response.
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Chapter 1
Introduction
1.1. Breast Cancer Metastasis
Breast cancer is the second cause of cancer related death in women. However,
the main cause of breast cancer mortality is metastasis. The American Cancer Society
(ACS) states that patients with metastatic breast cancer have poorer survival rates than
patients at earlier stages of cancer development (1). However, no treatment is currently
available to prevent or treat metastasis. This is in part because the regulators of
metastatic processes are not yet fully understood.
Breast cancer becomes metastasized when it spreads beyond the part of the body
where it originated. During metastasis, cancer cells break away from the primary tumor
and undergo multiple processes that lead to the formation of secondary tumors in distant
parts of the body. From primary tumors to form secondary tumors, cancer cells need to
go through sequential events called the metastatic cascade including invasion,
intravasation, extravasation, and colonization (2). The process of invasion starts once
cancer cells break away from the primary tumor mass. The detached cancer cells invade
the basement membrane and migrate through the surrounding stroma to reach the
nearby circulatory vessels in breast tissue. Cancer cells then intravasate as they penetrate
the lymphatic or vascular wall and travel through the circulation system. The traveling
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cancer cells then extravasate by invading the vascular wall into distant organs. Ultimately,
the cancer cells proliferate and form new tumors in their new location in processes called
colonization. The successful completion of the metastatic process is determined by the
ability of cancer cells to colonize in the distant organs (3, 4).
Over the past century, studies have been investigating regulators of metastasis
through different hypothesis such as the seed and soil hypothesis proposed by Stephen
Paget in 1989. Paget suggested that the metastatic cascade is highly controlled by two
main factors: the seeds, cancer cells, and the soil, the tissue microenvironment (5). This
section will review the seed and the soil of breast cancer, focusing on the role of
mammary soil in regulating metastasis.
1.1.1. Breast Cancer Cells: “The Seeds”
Breast cancer is a complex disease that is derived from the epithelial components
of the mammary gland. Breast cancer can initiate from different mammary epithelial cells
including: stem cells, luminal progenitor, or luminal differentiated cells (6, 7). Emerging
evidence indicates that the origin of cancer cells may define the molecular and the cellular
content of the resulting tumor (8, 9). Breast cancer can be classified into six molecular
subtypes: luminal A, luminal B, basal like, HER2+ enriched, normal breast and claudin-low
(10-12). Another classification of breast cancer is based on the hormonal receptor
expression by cancer cells: estrogen receptor positive (ER+), human epidermal growth
factor receptor 2 overexpressing (HER2+), and triple negative. For example, normal-like
and triple negative subtypes initiate from mutated mammary stem cells, whereas
mutations in luminal progenitor cells give rise to luminal B and HER2+ subtypes(13). The
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association between breast cancer subtype and metastatic activity has been documented
(14, 15). For example, studies have showed that the ER+ subtype is more likely to
metastasize to the bone, while HER2+ and triple negative subtypes metastasize to the
lung and liver (13, 16, 17).
1.1.2. Mammary Microenvironment: “The Soil”
The mammary gland is composed of two main components: the epithelium (ductal
network) and the stroma (fat pad), separated by the basement membrane. The mammary
microenvironment is composed of complex interactions between the epithelium and the
stroma (18, 19). Within the epithelial component, there are two distinct cell types: luminal
cells and basal cells which produce and attach to the basement membrane. Each cell type
further contains subpopulations of cells with different levels of differentiation. The
luminal compartment is composed of luminal progenitor cells and differentiated luminal
cells (20-23). The basal compartment is composed of mammary stem cells, myoepithelial
progenitor cells, and differentiated myoepithelial cells (24, 25). The ductal network is
formed by an outer layer of basal cells and an inner layer of the luminal cells. The
mammary ducts are surrounded by the stroma comprised of multiple components
including: adipocyte, fibroblast, immune cells, blood vessel, and extracellular matrix (18,
19, 26).
The mammary microenvironment is increasingly recognized as a major regulator
of normal and cancer development. During normal development, mammary glands
undergo different developmental stages: embryonic, puberty, pregnancy, lactation, and
involution. The epithelial component of the mammary gland arises from the mammary
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placodes which are derived from the ectoderm (27, 28). Mammary placodes then grow
into the primary mammary duct or rudiment. Meanwhile, the stroma is derived from
dermal mesenchyme. The formation of mammary ducts from the placodes is highly
controlled by the surrounding mesenchymal signaling (29, 30). The epithelial ducts then
undergo rapid growth during puberty. Ovarian hormones and growth factors signal from
stromal components initiate growth and differentiation of the epithelial cells within the
primary ducts (19, 31). In addition to the stromal signals, studies have shown that
epithelial differentiation is also regulated by the epithelial subpopulation within the ducts
(32, 33). Then, the epithelial cells undergo cycles of proliferation and apoptosis during
late developmental stages (pregnancy, lactation, and involution) followed by proliferation
and remodeling of the stromal component (34, 35). Taken together, the mammary
microenvironment controls the mammary gland during multiple different normal
developmental stages.
1.2. Role of Mammary Microenvironment in Metastasis
When neoplasia occurs, cancer cells interact with the local microenvironment to
create a new framework that supports tumor growth, called the tumor
microenvironment. Studies suggest that interactions between cancer cells and the local
tissue microenvironment determine metastatic behavior. In addition to cancer cells, the
tumor microenvironment is composed of multiple distinct cell types including the normal
mammary cells and recruited cells such as immune cells. The non-malignant cells within
the tumor microenvironment are called tumor-associated cells and are known to be
active participants in tumor progression and metastasis. Through interactions with
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tumor-associated cells, cancer cells undergo genetic modifications which enable them to
disseminate from the primary tumor and invade surrounding tissue (36).
Dissemination or detachment of cancer cells from the primary tumor mass is the
initial step for the metastatic cascade. Dissemination is found to be tightly associated with
epithelial-mesenchymal transition (EMT), a process in which epithelial cells undergo
multiple changes to gain mesenchymal properties during embryogenesis. Increasing
evidence shows that the tumor microenvironment stimulates EMT in cancer cells through
the activation of the same pathways as those activated during embryogenesis. EMT,
embryonic and in cancer cells, is characterized by loss of E-cadherin which results from
mutations in the E-cadherin gene that disrupt its function. Also, losing E-cadherin can
result from decreasing its expression as a subsequent step for the activation of
transcriptional factors such as Snail, Slug, Twist and FOXC2. Moreover, studies in colon
cancer show that decreasing E-cadherin gene expression and stimulating EMT in cancer
cells can also be mediated by TGFβ signaling. TGFβ-induced EMT is found to be triggered
by TNF-α produced by infiltrated macrophages (37, 38). Furthermore, the disruption of Ecadherin is associated with expressions of N-cadherin, mesenchymal cadherin, which
facilitates motility and migration of cancer cells within the surrounding stroma (39).
During migration, stroma-associated cells regulate tumor cell invasion through
different signaling pathways. For example, mesenchymal stem cells can stimulate
invasion behavior in cancer cells through CCL5 production. It is found that CCL5 promotes
the secretion of metalloproteinase MMPs which act by breaking down the extra cellular
matrix (ECM), thereby increasing the motility of cancer cells (40). Also, tumor-associated
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macrophages (TAMs), another stroma-associated cells, promote cancer cell invasion
through the secretion of epidermal growth factor and producing matrix-degradation
enzymes such as MMPs (41). The tumor microenvironment then supports tumor cells
intravasation and survival through the vascular system. Experimental evidence has shown
that macrophages help tumor cells to intravasate into the blood vessel through their
interactions with endothelial barriers (42). Extravasation and secondary tumor formation,
the final steps of the metastatic cascade, are found to be highly regulated through tumor
microenvironment signaling (43). It is suggested that the tumor microenvironment
regulates cancer cells colonization in distant organs through pre metastatic signaling (44).
Taken together, the tumor microenvironment is pivotal in each step of metastatic
cascade. Therefore, understanding the role of mammary microenvironment in metastasis
is crucial step to developing new therapeutic targets.
1.3. Limitation in Understanding Role of Mammary Microenvironment in Metastasis
The role of the microenvironment in tumor progression and metastasis has been
investigated over the past years. However, these studies are either correlative or limited
to specific components of the microenvironment. While the mammary microenvironment
is composed on two main component, most studies have been focusing only on the role
of the stromal component in regulating metastasis (45). One of the reasons is that studies
are using breast cancer mouse models where tumors are generated within the mammary
stroma (fat pad) and bypassing the epithelium. In an attempt to overcome this limitation,
we will be including the epithelial components when studying the role of tumor
microenvironment by generating tumors intraductally.
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It has been shown that the epithelial component plays a crucial role in regulating
cell fate. Experimental studies indicate that mammary epithelial cells can redirect somatic
cells from other organs (testes and nerve) as well as transformed cells into cells that form
a functional mammary outgrowth (46-49). Therefore, failure to consider effects of the
epithelial component may be a significant omission in understanding the role of the
mammary microenvironment in metastasis. Moreover, human breast cancer originates
within the epithelial microenvironment and then interacts with the stroma. Therefore,
we hypothesize that the epithelium plays a role in regulating the breast cancer metastatic
cascade which has not yet been studied. This hypothesis will be tested in chapter 2.
1.4. Role of Macrophages in Breast Cancer
In breast cancer, the immune cell component of tumor microenvironment plays a
crucial role in regulating tumor progression and metastasis. Tumor associated
macrophages are the major immune cells in the tumor microenvironment (50, 51).
Macrophages are a cell population of the innate immune system which are derived from
the myeloid lineage. They display high plasticity to adapt to their microenvironmental
signaling through changing their phenotypes (52). Two major phenotypes of macrophages
have been reported in the tumor microenvironment: M1 macrophages and M2
macrophages (52). M1 macrophages, or classically activated macrophages, are the proinflammatory phenotype which support tissue defense. M2 macrophages, or alternatively
activated macrophages, are the anti-inflammatory phenotype which support tumor
growth and disease progression (51, 53).
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Macrophage polarization is highly regulated by tumor microenvironmental
signals. During tumor initiation: inflammatory signals such as IFN-γ and TNF-α stimulate
macrophages to adapt the M1 phenotype. M1 macrophages secret high levels of
inflammatory cytokines, such as IL-12 and IL-23, and reactive oxygen and nitrogen species
which increase macrophages’ killer activity (53, 54). It has been known that M1
macrophages can recognize and destroy cancer cells and their presence in tumors
increase the effectiveness of immunotherapy. Increase M1 infiltration is correlated with
good prognosis in different cancers (55, 56). The cytotoxic activity of M1 macrophages
toward cancer cells can be through different mechanisms including direct interaction,
phagocytosis, and cytokines signaling. Studies have shown that macrophages are able to
selectively kill cancer cells by phagocytosis. Also, macrophage cytotoxicity is mediated by
the production of TNF-α (57-59). Experimental studies indicated that macrophage
vaccination of mice can attenuate tumor growth through direct killing of tumor cells by
M1 macrophages (59).
However, signaling from cancer cells can promote macrophages polarization to
M2 phenotype, or tumor-associated macrophages (TAMs). M2 macrophages are induced
by the secretion of anti-inflammatory signals such as IL-4 and IL-13 (50, 52). In breast
cancer, studies have shown that increasing M2 infiltration is associated with reduced
patients’ survival rates (60, 61). Experimental evidence indicates that TAMs play a critical
role in supporting tumor progression and metastasis through different pathways (51, 53).
TAMs have a pivotal role in promoting tumor growth. It has been demonstrated that
TAMs facilitate cancer cell proliferation through secretion of growth factors such as EGF
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and FGF (62). TAMs also support tumor growth by reducing anti-tumor immunity. TAMs
secrete high levels of IL-10 which suppress cytotoxic T-cell and natural killer (NK) cell
activity(63). Moreover, TAMs promote tumor growth via stimulating angiogenesis. It has
been reported that TAMs produce a wide spectrum of growth factors such as VEGF, PDGF
and TGF-β to modulate and induce neovascularization (51, 53). It also has been shown
that TAM-derived MMPs can facilitate angiogenesis, in particular MMP9, which helps
degrade ECM and further release growth factors (64). In addition to promoting
angiogenesis, TAM-derived MMPs promote cancer cell migration through the stromal
tissue which is one of first steps of the metastatic cascade (64). Using breast cancer mouse
models, it was found that co-injection of M2 macrophages with cancer cells significantly
increases their metastatic activity (65). Further studies showed that TAMs support cancer
cell intravasation into the vascular system (66, 67). Furthermore, TAMs can also facilitate
cancer cell metastasis through ECM remodeling (68). TAMs have also been found to
support the growth of cancer stem cells, which positively correlated with tumor
progression and metastasis, through juxtacrine signaling (69).
Due to the important role of TAMs in tumor progression and metastasis, TAMs are
considered as strong therapeutic target. Several strategies have been developed over the
past years to inhibit TAMs activity within the tumor microenvironment including:
inhibiting TAMs recruitment, blocking TAMs activation signaling, and inducing TAMs repolarization (70, 71).
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1.5. Emodin and Breast Cancer
In recent years, an increasing number of research uses natural compounds as a
source of new drugs. Natural products isolated from Chinese herbs have been found to
have biological activities (72, 73). Emodin, a trihydroxy-anthraquinone, is the active
compound of several Chinese herbs. It has been shown that emodin has antiinflammatory and anti-cancer properties (74). In different experimental disease models,
emodin treatment was found to attenuate inflammation by targeting the macrophage
population through different mechanisms (74-76). Emodin reduces the production of
inflammatory cytokines such as TNF-α, IL-1β, and IL-6 and can also reduce macrophage
infiltration (76). Moreover, emodin regulates macrophage activation through blocking
NFκB and MAP kinase signaling (74). It also has been shown that emodin can regulate
macrophage phagocytosis, migration, and polarization (77).
Emodin’s role in regulating the macrophage component makes it as a potential
therapy for cancer. Experimental studies have shown that emodin treatment reduces
tumor growth in different pre-clinical animal models (74, 78). However, most of these
studies are focusing on the direct effect of emodin treatment on cancer cells. Different
mechanisms have been proposed by which emodin represses tumor growth. Studies have
found that emodin inhibits NFκB, ERK 1/2, p38, JUNK and PI3K/AKT signaling pathways in
different cell lines (78). Also, emodin induces apoptosis in many cancer cell lines through
different pathways including caspase dependent and independent pathways (79-81). On
the other hand, few studies have found that emodin treatment can modulate the tumor
microenvironment. Emodin was found to inhibit angiogenesis in pancreatic cancer model
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through reducing NF-κB signaling and its regulation of angiogenesis-associated factors
VEGF, MMP-2, MMP-9, and eNOS (82). Emodin can also inhibit angiogenesis by
attenuating endothelial cell proliferation, migration and tube formation through blocking
VEGF-A receptor-2 (KDR/Flk-1) signaling (83). In addition to its role in angiogenesis,
emodin has been shown to reduce tumor growth and lung metastases by targeting
macrophages. Using breast cancer mouse models, emodin attenuates tumor growth by
inhibiting macrophage infiltration and M2 phenotype polarization in tumors (84). Emodin
can also reduce lung metastasis through reducing M2 macrophages infiltration into lung
tissue (85).
1.6. Breast Cancer Laterality and the Mammary Microenvironment
Based on epidemiological studies, breast cancer is a lateralized disease with more
tumors forming in the left breast (86-91). However, right-sided tumors are more
aggressive and have earlier metastatic development (88, 90, 91). Moreover, some studies
indicate that patients with right-sided breast cancer have poorer overall survival rates
than patients with left-sided breast cancer (91-93). Although these finding indicate leftright differences in tumor biology, no functional studies exist to identify the causes of
these left-right difference. In an attempt to overcome this limitation, we will study the
left-right differences in tumor biology, metastasis, and therapeutic response.
Mammary glands develop as paired structures, and it has been known that
developmental signals are unique for each gland (94, 95). During embryonic
development, the formation of mammary placodes, which form the ducts, seems to be
enhanced in the left side (94). Also, somites which contribute to mammary gland
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formation, particularly the stromal components, have left-right differences in gene
expression (96, 97). Moreover, in different developmental stages, it has been
demonstrated that mammary glands are molecularly lateralized despite their similar
morphology (92).

A microarray analysis of mouse mammary glands yielded 161

transcripts that are left-right differentially expressed, including genes known to regulate
mammary tumorigenesis (92).

Knowing that mammary glands exhibit left-right

differences at the molecular level allows us the opportunity to test the role of the
microenvironment in breast cancer laterality by using the same seed. This hypothesis will
be tested in chapter 3 and 4.
1.7. Specific Aims and Significance
In this study we will investigate the role of the mammary microenvironment in
promoting left-right differences in breast cancer progression, metastasis, and therapeutic
response. We developed three specific aims: 1) Determine if the mammary epithelial
microenvironment has an effect on tumor progression and/ or metastasis when
compared to the stromal microenvironment. 2) Determine if the mammary
microenvironment promotes left-right differences in tumor progression and/ or
metastasis. 3) Determine if left versus right mammary tumors respond differently to
emodin treatment.
The mammary microenvironment is composed of two main components:
epithelium and stroma(18). However, breast cancer mouse models are generated by
incubating tumor cells into the stromal microenvironment and altogether bypassing the
epithelial microenvironment. Strong evidence shows that the epithelium is an important
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component of the mammary microenvironment (46-48, 98). Moreover, human breast
cancer originates within the epithelial components. Therefore, specific aim one will test
the hypothesis that the mammary epithelial microenvironment influences tumor
progression and metastasis when compared to the stromal microenvironment. To test
this hypothesis, we will generate the mammary tumor within the epithelial
microenvironment using an intraductal injection of tumor cells. Tumor growth rate,
tumor histopathology, molecular profile will be examined for the intraductal generated
tumors and compared to what has been reported for stromal generated tumors of the
same cancer cells. Chapter 2 will show that adding the epithelial component impacts
mammary tumor properties. Using an intraductal mouse model will provide more insight
on overlooked tumor progression and/ or metastatic regulators which may lead to the
development of new therapeutic strategies.
Knowing that the normal mammary microenvironment exhibits left-right
differences at the molecular level (92), specific aim two will investigate if left and right
mammary microenvironments will support tumorigenesis differently. Epidemiological
studies show that more aggressive tumor subtypes more often form in the right breast.
Moreover, patients with right side breast tumors have poorer survival rate (88, 90-92,
99). These findings suggest left-right differences in tumor biology depend on tumor
location, which suggests left-right differences in the microenvironmental support to these
tumors. Therefore, the second specific aim will test the hypothesis that left versus right
mammary microenvironments differently support tumor progression and metastasis. To
test this hypothesis, we will inject the same number of the same cancer cells into either
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left or right mammary glands. Molecular profile, macrophage content and polarization,
and metastatic activity will be examined for left versus right tumors. These results will
demonstrate for the first time that the right mammary microenvironment promotes more
M2 macrophages, resulting in more aggressive tumors with more metastatic activity.
Understanding the left-right differences in tumor biology is essential to better
understanding clinical outcomes in breast cancer patients.
There has been an increasing interest in using natural compounds isolated from
Chinese herbs as a source of new cancer therapy. Emodin, the active ingredient of several
Chinese herbs, is known to have anti-cancer activity through targeting cancer cells and
their microenvironment (72, 80, 82, 83). Emodin’s ability to target tumor
microenvironment, particularly M2 macrophages, makes it as a potential breast cancer
therapy. Knowing that the mammary microenvironment promotes left-right differences
in M2 macrophages polarization, specific aim three will test the hypothesis that left versus
mammary microenvironments respond differently to emodin treatment. To test this
hypothesis, mice bearing left versus right tumors will be treated with emodin.
Macrophage content and polarization, stem cell content, and metastasis will be examined
for left versus right emodin treated tumors. These results will demonstrate for the first
time that mammary tumors exhibit left-right differences in therapeutic response. These
results indicated that tumor side is an important aspect to consider for clinical treatment
of breast cancer patients.
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Chapter 2
Role of epithelial microenvironment in mammary tumors progression and
metastasis
2.1. Introduction
Although metastatic breast cancer is the main cause of death in breast cancer
patients, there is still no treatment available to treat or prevent metastasis. In part, most
preclinical mouse models used to study tumor progression and metastasis do not fully
recapitulate human breast cancer conditions (100, 101). One of the reasons for this
limitation is that the mammary gland contains two distinct microenvironments: the
epithelium, ductal network, and the stroma, fat pad. Human breast cancer originates
within the epithelial microenvironment, but breast cancer mouse models are generated
by delivering tumor cells into the stromal microenvironment using fat pad injection and
bypassing the other microenvironment, the epithelium (102). Lots of studies have shown
that the stromal microenvironment plays a major role in regulating tumor progression
and metastasis (36, 45, 103). However, strong evidence demonstrates that mammary
epithelial cells are able to regulate cells of non-mammary origin as well as transformed
cells’ fate such as adult testicular cells, bona fide neural stem cells, MMTV-neutransformed cells, and human embryonal carcinoma cells (46-49, 98). Thus, failure to
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consider effects of the epithelial microenvironment might be a significant omission in
developing mouse models that recapitulate human breast cancer conditions.
Some mouse models have been adapted to include the effects of the epithelial
microenvironment in studying mammary tumor initiation such as ductal carcinoma in situ
mouse models. In these models, an intraductal injection delivers tumor cells directly into
the epithelial microenvironment through the teat (104, 105). However, using this
approach in studying tumor progression and metastasis is still limited. A study
investigated the effects of the epithelial microenvironment on tumor progression and
metastasis using a metastatic mouse model. Sflomos et al. showed that when ER+
(Estrogen Receptor positive) tumor cells are implanted into the epithelial
microenvironment, they grow and metastasize differently compared to fat pad
implantation of the same tumor cells. Furthermore, they showed that different tumor
behavior is due to different microenvironmental signaling, epithelium versus stroma
(106).
Another reason for the limitation in developing breast cancer mouse models is
that mice have five pairs of mammary glands, and it has been reported that each
mammary gland is different in its normal development and susceptible to pathogenesis
(94). Human breasts are located anatomically in the thoracic area while most of the fat
pad generated tumors are established in the fourth pairs of the mouse mammary glands
that are located in the inguinal area. Moreover, based on the anterior-posterior
anatomical location of human breasts, the thoracic glands, the third pair of the mouse
mammary glands, most closely model human breast anatomical location (94).
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Furthermore, the signaling pathways during mouse mammary gland development differ
amongst the five pairs and the signaling of thoracic glands closely model human breast
development (94). Thus, choosing the “wrong” mammary gland in mouse models may be
another significant limitation in developing breast cancer mouse models.
Attempting to overcome these two limitations in breast cancer mouse models, we
investigated whether adding the epithelial microenvironment and using mouse thoracic
glands can effect tumor progression and metastasis. In this study, we chose a widely used
mouse model for triple negative breast cancer, the 4T1 mouse model. In order to
determine if our approach gives different tumor progression and metastasis compared to
the currently used mouse models of the same tumor cells, several 4T1 tumor properties
were measured and compared to what has already been reported for 4T1 fat pad/inguinal
generated tumors. Here, we show that generating 4T1 tumors within the epithelial
microenvironment of thoracic glands change histological and molecular features of 4T1
tumors. Compared with previously reported fat pad 4T1 tumors, the resulting intraductal
tumors exhibited different properties, including faster growth rate, differences in
histopathological features, metastatic behavior, and gene expression profile. Taken
together, our results indicate that the epithelial microenvironment of the thoracic gland
promotes more aggressive 4T1 tumors compared to what has been reported for the 4T1
fat pad generated tumors.
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2.2. Material and Methods
2.2.1. Mice
All experimental methods were conducted under a protocol approved by the
Institutional Animal Care and Use Committee IACUC of the University of South Carolina
according to National Institutes of Health guidelines. Female BALB/c mice (16 weeks old,
22-25 gram in weight) were purchased from Jackson Laboratory. Mice were housed in the
University of South Carolina Animal Research Facility.
2.2.2. 4T1-Luc2-RFP Cell Line
The parental 4T1-Luc2 cell line was purchased from the American Type Culture
Collection (ATCC) which originally labeled with luciferase (Luc). Upon purchase this cell
line, red fluorescence protein (RFP) was inserted into the 4T1-Luc2 cell line using a pWPIRFP lentiviral vector. 4T1-Luc2-RFP cells were maintained in RPMI 1640 media
supplemented with 10% FBS, 100 U/ml penicillin (Sigma-Aldrich St. Louis, MO) and 100
µg/ml streptomycin (Sigma-Aldrich) at 37C° in a humidified CO2 incubator.
2.2.3. Intraductal Implantation of 4T1-Luc2-RFP Cells
Before implantation, 4T1-Luc2-RFP cells were allowed to grow for two days. Cells
from the second passage were collected, counted, and resuspended in sterile PBS at a 106
cells/ml concentration. Mice were anesthetized using isoflurane. 5 µl of cells suspension
(containing 5000 4T1-Luc2-RFP cells) was injected intraductally into the right thoracic
mammary glands of the anesthetized mice using a previously described method12, but
without surgically opening the mouse. Briefly, a Hamilton syringe with a 30-gauge bluntended 0.5-inch needle was used for the intraductal implantation. The mice were
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anesthetized and placed under a dissecting microscope. The teat of the thoracic gland
was snipped and the needle was inserted directly into the mammary duct through the
opening of the teat.
2.2.4. Monitoring Tumor Growth
After 4T1-Luc2-RFP intraductal tumors became palpable, tumor volume was
monitored by: (1) external caliper measurements, tumor volume was measured semiweekly using a digital calipers (tumor volume = (length * width2)/ 2).
(2) Bioluminescence imaging, mice were imaged weekly using IVIS Lumina system
(PerkinElmer) as previously described(107). Briefly, D-Luciferase (10 µg/gram of body
weight) was injected intraperitoneally (IP). Images were acquired 10 minutes following
the D-Luciferase injection. Live imaging software was used to quantify photons emitted
by the tumor cells.
2.2.5. Histology and Image Collection
Trichrome staining of paraffin embedded tissue was used for histological
examination (local invasiveness, necrosis, collagen deposition and fibrosis) of the primary
tumors. To study metastasis in distant organs such as lungs, liver, and spleen, standard
hematoxylin and eosin staining was performed. 25 sections were stained for each organ,
each set of 5 sections was collected from different levels within the organ. The stained
sections were examined and photographed using a Nikon Eclipse Ni microscope.
2.2.6. Immunofluorescence Staining of RFP
4 µm sections of 4% paraformaldehyde fixed and paraffin embedded tissue were
used for RFP immunofluorescence staining using the manufacturer’s protocol (Novus
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Biologicals, USA). Briefly, sections were deparaffinized in xylene and rehydrated through
graded ethanol series. Antigen retrieval was performed on slides heated in 10mM citrate
buffer (pH = 6.0) in water bath for 30 min at 95C°. After blocking with 5% donkey serum,
RFP primary antibody (Novus Biologicals, USA) was added in concentration of (3 µg/ml).
Slides were incubated for one hour at room temperature (RT) followed by overnight
incubation at 4C°. After washing, slides were incubated with secondary antibody (1µg/ml
- Alexa Fluor 594) for two hours at RT. DAPI staining was added for nuclear labeling
followed by mounting media and coverslips. Slides were photographed using a Nikon
Eclipse Ni microscope.
2.2.7. Isolating Tumor 4T1-Luc2-RFP Cells and RNA Isolation
4T1-Luc2-RFP cells were isolated from the 4T1-Luc2-RFP intraductal tumors by RFP
expression. Tumors were harvested at day 24 post tumor cells injection and processed for
single cell suspension. Briefly, tumor tissue (600-800 mg) were dissociated: first
mechanically using sterile scalpels into less than 1mm3 pieces and then enzymatically
using a mix of collagenase IV (4 mg/mL), Hyaluronidase (1 U/mL), and DNase I (20 µg/mL)
(Sigma-Aldrich St. Louis, MO) in 5mL of serum-free DMEM medium for 1 hour at 37C°
shaking water bath. After washing from the enzyme mix, pellets were resuspended in 5mL
RBC lysis buffer for 3 min at room temperature. After washing from the RBC lysis buffer,
the cell suspension was passed through a 70 µm cell strainer to obtain the single cell
suspension. RFP positive 4T1 cells were sorted using fluorescence-activated cells sorting
(FACS). The sorted RFP+ 4T1 cells were collected in tubes contain QIAzol lysis reagent and
processed for RNA extraction using Qiagen kit.
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2.2.8. RNA-Seq Analysis
Three independent RNA preparation from 4T1-Luc2-RFP cultured and intraductal
tumors’ FACS 4T1-Luc2-RFP cells were used to conduct RNA sequencing analysis. The
RNA-Seq libraries were created using the TruSeq RNA Sample Prep kit. Libraries were
sequenced on HiSeq 2500, following the manufacturer’s protocols. The mapping of the
processed reads was performed by using HISAT with mm10 reference genome; reads
were counted by using HTSeq (108, 109). Genes showing less than 10 counts on average
across all samples were removed, resulting in 14,027. The remaining values were
normalized with TMM normalization method and then transformed with voom
transformation (110, 111).
2.2.9. Statistical Analysis
For all the experiments, the data was represented as the mean ± standard error
of the mean (SEM). For RNA-Seq experiment: Limma package was used to examine
differential expression between the groups of interest, obtained p-value were corrected
with BH correction for multiple testing and genes exhibiting corrected p-value < 0.05 were
considered to be significant and were used in further analysis(112, 113). BINGO plugin in
Cytoscape environment was used to examine Gene Ontology (GO) Biological processes
(114, 115). Hierarchical clustering was performed by using gplots package (https://cran.rproject.org/web/packages/gplots/index.html).
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2.3. Results
2.3.1. The Epithelial Microenvironment Affects 4T1 Tumor Take and Tumor Latency
Compared to the Stromal Microenvironment
In order to determine if the differences in epithelial versus stromal
microenvironments affect 4T1 tumor take and tumor latency, we generated 4T1 tumors
within the epithelial microenvironment using the intraductal injection and compared our
results with what has been reported about the 4T1 fat pad generated tumors. The 4T1Luc2-RFP cells were injected directly in the epithelial ducts through the teat of the
thoracic mammary gland of adult female BALB/c mice (Fig. 2.1). After 7-10 day of the
intraductal injection, 4T1-Luc2-RFP cells give rise to a palpable tumors with 100% primary
tumor take. This results are different compared to what have been reported for the fat
pad generated tumors when injected the same number of cells. 4T1 fat pad tumors
become palpable at earlier time at 3-5 days post injection but with less tumor take of 96%
(116).
2.3.2. The Epithelial Microenvironment Effects 4T1 Tumor Growth Rate Compared to
the Stromal Microenvironment
Starting at day 11 post tumor cell injection, tumor growth was monitored over the
experimental time using two standard methods: First, the 4T1 cells that we used in this
study were labeled with luciferase which allowed for in vivo monitoring of tumor growth
using an in vivo imaging system (IVIS). The luminescence data of 4T1-Luc2-RFP intraductal
tumors showed an increase in tumor mass over the five weeks of the experimental time
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(Fig. 2.2 a, b). Second, tumor volume was also monitored semi-weekly using a digital
caliper which showed that 4T1-Luc2-RFP intraductal tumors reached an average 2 cm3 in
volume (Fig. 2.2 c) and an average 2 g in weight (Fig. 2.2 d) at five weeks post-injection.
Though the 4T1 fat pad tumors started their growth earlier than the 4T1 intraductal
tumors, the fat pad generated tumors have an average of 1 cm3 tumor volume at 40 days
post injection (84, 85). Our results indicate that the epithelial microenvironment
moderately increase growth rate of 4T1 tumors compared to what has been reported in
the literature for fat pad 4T1 tumors.
2.3.3. The Epithelial Microenvironment Significantly Affects Collagen Deposition and
Fibrosis in 4T1 Tumors Compared to the Stromal Microenvironment
Upon the experimental end point, we examined the histopathology of the 4T1Luc2-RFP intraductal tumors to determine if including the epithelial microenvironment
generates different pathological features compared to what has been reported for the fat
pad 4T1 tumors. Several histopathological features were examined for 4T1-Luc2-RFP
intraductal tumor sections stained with trichrome staining, including local muscle
invasion (Fig. 2.3 a), collagen deposition and fibrosis (Fig. 2.3 b), and immune cell
infiltration (Fig. 2. 3 c). Based on the literature, all of the above histopathological features
can be seen in the fat pad 4T1 tumors except for collagen deposition and fibrosis which
has not been reported in fat pad 4T1 tumors (117-119).
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2.3.4. The Epithelial Microenvironment Significantly Affects 4T1 Metastatic Behavior
Compared to the Stromal Microenvironment
Based on the fat pad generated tumors of 4T1-Luc2 variant that we used in this
study, 4T1-Luc2 cells have not reported to metastasize outside of the lung (84, 85). To
determine if including the epithelial microenvironment when generating 4T1-Luc2-RFP
tumors affects their metastatic behavior (including tropism and metastatic burden) when
compared to fat pad generated tumors, we examined several organs such as lungs, liver,
spleen, brain and bone for the presence of metastatic lesions. Metastatic lesions were
only found in the lung (Fig. 2.4 a) which matches to what has been reported for the 4T1Luc2 variant used in fat pad generated tumors (84, 85). Although no metastatic lesions
were found in other organs, the histopathology of the spleen and the liver revealed
extensive extramedullary hematopoiesis by week five post tumor cell injection (Fig. 2.4 c,
d). Our data indicated that incubating 4T1-Luc2-RFP cells within the epithelial
microenvironment does not change the tropism of the 4T1-Luc2-RFP cells.
To assess the metastatic burden of 4T1-Luc2-RFP intraductal generated tumors,
we examined the lung sections for metastatic lesions after hematoxylin and eosin
staining. The histopathological examination showed that the number of mice with macrometastases increased from week three to week five (87% of the mice at week three, 100%
at week five) (Fig 2.4 b). Also, the number of the lung lesions increased from an average
of 2 macro-metastases at week three to an average of 4 macro-metastases at week five
(n=8 at three weeks time point and n=6 at five weeks time point) (Fig. 2.4 b). Comparing
to what has been known for fat pad 4T1 tumor metastasis, our results indicate a
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significant increase in metastatic activity of 4T1-Luc2-RFP cells after the intraductal
implantation, particularly at three weeks time point. The percentage of mice with lung
macro-metastases is 0 % at three weeks and 83 % at five weeks post the fat pad
implantation (116, 120), while we found that the percentage of mice with lung macrometastasis is 87 % at week three and 100% at week five post the intraductal implantation.
2.3.5. The Epithelial Microenvironment Affects the Fluorescence Expression of 4T1 Cells
Similarly to the Stromal Microenvironment
In order to assess the molecular change in 4T1 cells after the intraductal
implantation, we used RFP tagged 4T1 cells to generate the intraductal tumors. First, we
examined if the 4T1 cells maintain their RFP expression after intraductal implantation by
staining 4T1 intraductal tumor sections with anti-RFP antibody. Our results show that 2530% of the cells in the 4T1 intraductal tumor section are RFP positive cells (Fig. 2.5). This
data shows that 4T1-Luc2-RFP cells maintain their fluorescence expression after the
intraductal implantation. This is similar to previously published studies which show that
fluorescently labeled 4T1 cells, 4T1-GFP and 4T1-RFP, maintain their fluorescence
expression after the fat pad implantation (116, 121, 122).
2.3.6. The Epithelial Microenvironment Significantly Affects 4T1 Gene Expression and
Pathway Analysis Compared to the Stromal Microenvironment
To determine molecular changes within 4T1 cells after implantation in the
epithelial microenvironment, we isolated RFP tagged 4T1 cells from the intraductal
tumors using fluorescence activated cell sorting (FACS). Then, we conducted RNA
sequencing for the isolated 4T1-Luc2-RFP cells and compared them to non-injected 4T1-
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Luc2-RFP cells. The gene expression profiling revealed 6,374 genes that are differentially
expressed in the isolated 4T1-Luc2-RFP cells from the intraductal tumors compared to
non-injected 4T1-Luc2-RFP cells, as shown in the heat map (Fig. 2.6 a). Our results for the
differential gene expression are significantly different from what has been reported for
the molecular analysis of 4T1 cells isolated from fat pad generated tumors. Only 395
genes are differentially expressed in the fat pad isolated 4T1 cells compared to noninjected 4T1 cells (123), and there are only two genes that are common between 4T1 cells
isolated from intraductal versus fat pad tumors (Fig. 2.6 b).
We next subjected the upregulated genes to Gene Ontology analysis, focusing on
Biological Processes component, which showed significantly affected processes
associated with the intraductal implantation of the 4T1-Luc2-RFP cells (Fig. 2.6 c). When
compared our result to the pathways that affected by the fat pad implantation, we found
that many of these pathways have not been reported to be affected by the fat pad
implantation of the 4T1 cells. Immune processes was the pathway most affected by
intraductal implantation of the 4T1 cells. Of these pathways are known to regulate tumor
progression through modulating TAMs activation such as IL-10, IL-4, and IL-6 signaling
pathways (124, 125). Other immune processes reported in the intraductal effected
pathways are reported to regulate tumor immune microenvironment such as IFN gamma
and toll-like receptor (126, 127). Moreover, some pathways affected by intraductal
implantation are not reported to be effected by fat pad implantation, such as
angiogenesis, wnt signaling, JAK-STAT signaling, and Ras signaling, which are known to
directly support tumor progression and metastasis.
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2.4. Discussion
Our results demonstrate that the epithelial microenvironment differentially alters
4T1-Luc2-RFP tumor properties, such as growth rate, tumor histopathology, metastatic
properties, and molecular profiles when compared to what has been reported in the
literature for 4T1 fat pad generated tumors. Our results also indicate that many of the
intraductal tumor properties are associated with more aggressive tumors. Collagen
deposition and fibrosis associated with 4T1 intraductal tumor histopathology has not
been reported for 4T1 fat pad tumors and is consistent with more aggressive tumors (68,
103, 128). Thus, using the intraductal mouse model offers opportunity to study and follow
these important histopathological changes throughout tumor progression and
metastasis.
With the metastatic properties of 4T1 intraductal tumors, our data shows that the
epithelial microenvironment promotes a higher percent and earlier lung metastases
compared to what has been reported for 4T1 fat pad generated tumors. Studies have
shown that using fat pad implantation of 4T1 cells requires at least 40,000 cells in order
to get 100% lung metastasis (107, 116, 129, 130). However, our results show that
intraductal implantation of a small number of tumor cells (5000 4T1-Luc2-RFP cells) can
achieve 100% lung metastasis by five weeks post injection. Moreover, our results show
that lung macro-metastasis presents as early as three weeks post intraductal injection
while it needs five weeks post fat pad injection to find lung macro-metastases (116).
Our data also shows that the epithelial microenvironment alters 4T1-Luc2-RFP
gene expression profile when compared to non-injected 4T1-Luc2-RFP cells. Our data of
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RNA sequencing analysis of 4T1-Luc2-RFP cells isolated from the intraductal tumors
versus the cultured 4T1-Luc2-RFP cells yielded 6,374 differentially expressed genes. Other
studies that used fat pad implantation of 4T1 cells showed that around 395 genes were
differentially expressed when compared with the parental 4T1 cells (123). Many genes
associated with the isolated intraductal 4T1-Luc2-RFP cells are consistent with triple
negative breast cancer progression and metastasis, such as Hoxb, Acta2, Actg2, and Wnt
(131, 132). These genes have not been reported to be expressed in 4T1 fat pad generated
tumors. This indicates that the intraductal model of 4T1 cells offers greater opportunities
to study the metastatic cascade than the fat pad model of 4T1 cells.
Moreover, some of the genes associated with the isolated intraductal 4T1-Luc2RFP are associated with therapeutic response. One such gene, cytotoxic T-lymphocyte
antigen-4 (Ctla4), is up-regulated (87 fold change) in these cells. Ctla4 is a protein-coding
gene which transmits an inhibitory signal to immune cells (T-cells in particular) (133).
Tremelimumab, a monoclonal antibody specifically for Ctla4, has been recently used in
clinical trials alone or in combination with other anticancer therapeutics to treat patients
with metastatic breast cancer (134). While studies have found that the anti-Ctla4 alone
has no effect on 4T1 fat pad tumors (135), our results indicate that the intraductal model
of 4T1 cells will be a better model to examine anti-Ctla4 therapeutic strategies. Androgen
receptor AR is another up regulated gene (65 fold change) in 4T1 cells after the intraductal
implantation and has been used as a therapeutic target in different breast cancer
subtypes (136). Enzalutamide, targeting AR signaling pathways, has been used in clinical
trials to treat patients with triple negative breast cancer (ASCO abstract 1003); however,
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4T1 fat pad generated tumors have not been reported to be used to test this therapeutic
strategy. Our data of Androgen expression indicates that our approach of including the
epithelial microenvironment make it a good model to test these therapeutic strategies.
Furthermore, subjecting the upregulated genes to pathway analysis yields over 90
different pathways that are affected by the intraductal implantation. Immune processes
were the most effected pathways by the epithelial microenvironment. Some of these
pathways play a crucial role in regulating tumor progression and metastasis through
modulating the tumor immune-microenvironment such as IFN-gamma and toll-like
receptor or regulating TAMs activation such as IL-10, IL-4, IL-6 (124-127). Our results also
show some pathways that have not been reported to be affected by the fat pad
implantation such as angiogenesis, wnt signaling, JAK-STAT signaling, and Ras signaling,
(123). These results indicate that including the epithelial microenvironment in generating
mammary tumors offers a mouse model that allows the study of these pathways.
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Figure 2.1: Schematic shows the intraductal injection of 4T1-Luc2-RFP cells into the right
thoracic mammary glands of BALB/c mice. The needle was inserted directly into the
opened teat of the mammary epithelial ducts.
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Figure 2.2: Growth progression of 4T1 intraductal tumors. (A) Mice were imaged on a
weekly basis by IVIS starting with second week post-injection to monitor tumor growth as
shown in a representative mouse. (B) Photon flux per second (ph/sec) was measured
using IVIS to monitor tumor growth (n=6). (C)Tumor volume was also monitored semiweekly using digital calipers (n=6). (D) 4T1 tumor weight was measured upon sacrifice
(n=6).
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Figure 2.3: 4T1 tumor histopathology. Trichrome staining of a 4T1-Luc2-RFP primary
tumor section illustrating different pathological features including neoplastic muscle
invasion (M=muscle) (T= tumor) (A), fibrosis and collagen deposition (B), and necrosis
infiltrated by leukocyte (C) (200x) (scale bar = 50µm).
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Figure 2.4: Metastases to lungs and increased hematopoiesis in liver and spleen.
Hematoxylin and eosin staining of: (A) a lung section showing macro-metastases in the
lung. (B) The percentage of mice with lung macro-metastasis and the number of macrometastasis per lung at two different time points (3 and 5 weeks). (C) A liver section
showing islands of extramedullary hematopoiesis, and (D) a spleen section with extensive
extramedullary hematopoiesis as evidenced by the presence of megakaryocytes (arrow
heads) (200x) (scale bar = 50 µm).
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Figure 2.5: RFP expression in 4T1-Luc2-RFP cells. Immunofluorescence staining of a 4T1
primary tumor section shows (A) the percentage of RFP positive cells, and (B) the RFP
expression in tumor cells (white arrows) (600 X) (scale bar = 25 µm)
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Figure 2.6: Distinct gene expression profiling associated with the intraductal
implantation of 4T1-Luc2-RFP. (A) A heatmap displaying 6,375 genes that differentially
expressed after the intraductal incubation of 4T1-Luc2-RFP compared to non-injected
4T1-Luc2-RFP. (B) Identification of differentially expressed genes (DE) in 4T1-Luc2-RFP
post-intraductal incubation compared to Tabaries et. al. data of differentially expressed
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genes in 4T1 cells post-fat pad incubation (Venn diagrams). (C) Pathway analysis of
differentially expressed genes in 4T1-Luc2-RFP post-intraductal incubation.
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Chapter 3
Role of Mammary Microenvironment in Promoting Left-Right Differences
in Tumor Progression and Metastasis
3.1. Introduction
Although breast cancer continues to be the most common cancer diagnosis for
women worldwide, the main cause of breast cancer related death is metastasis (137). To
address the mechanisms underlying metastatic processes, several investigators proposed
different hypotheses. The seed and soil hypothesis proposed by Stephen Paget 1989 is
the most common hypothesis to explain the factors regulating cancer metastasis (5).
Using this hypothesis, a growing number of studies highlighted the importance of the
seed (cancer cells) as well as the soil (tissue microenvironment) of metastatic sites in
regulating metastatic processes (36, 138). However, the effect of the primary tumor
microenvironment in regulating metastasis has been ignored. Therefore, studying the role
of the mammary microenvironment in regulating breast cancer metastasis will uncover
unappreciated factors that contribute to metastatic processes.
Breast cancer originates in mammary glands, particularly within the epithelium.
When carcinoma occurs, the primary tumor not only contains cancer cells but also
different cell types that are recruited to the primary tumor location, all of which make up
the primary tumor microenvironment (139, 140). During tumor progression, cancer cells-
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recruited cells interactions play a major role in regulating the primary tumor
microenvironment to support tumor growth and metastasis. In addition to that, normal
components of the mammary glands are still present within the primary tumors.
However, the role of the normal components in tumor progression and metastasis has
not yet been studied. In an attempt to overcome this limitation, this study aimed to
investigate the role of the mammary microenvironment in tumor progression and
metastasis.
Mammary glands develop as paired structures, and it has been known that
developmental signals are unique for each gland (94, 95). Moreover, it has been
demonstrated that despite their morphological symmetry, there are transcriptional
differences in left versus right mammary glands in mice (92). A microarray analysis of
mouse mammary glands yielded 161 transcripts that are left-right differentially
expressed, including genes known to regulate mammary tumorigenesis and therapeutic
sensitivity. Knowing that mammary glands exhibit left-right differences at the molecular
level allows us the opportunity to study the effect of molecularly different mammary
microenvironments (soils) on metastatic behavior while using the same cancer cells
(seeds).
To

determine

if

there

are

left-right

differences

in

the

mammary

microenvironmental support of tumor progression and /or metastatic behavior, we have
performed functional studies using the 4T1 TNBC mouse model. Metastatic 4T1-Luc2-RFP
(luciferase; Red Fluorescent Protein) mammary carcinoma cells were incubated in either
the left or right mammary glands. Several features of tumor progression and metastasis
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were monitored over the experimental time and compared between left versus right
tumor groups. Here we show that despite their equivalent growth rate and end point
mass, left and right tumors are different in their molecular profile, histopathological
features, and metastatic behavior. This study presents for the first time the unappreciated
role for the left versus right mammary microenvironments in the specification of tumor
progression and metastasis. Moreover, we determine the clinical relevant of our mouse
data using the publically available breast cancer data bases. Our results show that human
breast tumor exhibit left-right differences in their genomic profile and our mammary
tumor mouse signature is linked to human survival rates.

3.2. Material and Methods
3.2.1. Mice
All experimental methods were conducted under a protocol approved by the
Institutional Animal Care and Use Committee IACUC of the University of South Carolina
according to National Institute of Health guidelines. Female virgin BALB/c mice (16 weeks
old, 22-25 gram in weight) were purchased from Jackson Laboratory. Mice were housed
in the University of South Carolina Animal Research Facility.
3.2.2. 4T1-Luc2-RFP Cell Line
The parental 4T1-Luc2 cell line was purchased from American Type Culture
Collection (ATCC) were originally labeled with luciferase (Luc), and labeled with RFP as
described in chapter 2. 4T1-Luc2-RFP cells were maintained in RPMI 1640 media
supplemented with 10% FBS, 100 U/ml penicillin (Sigma-Aldrich St. Louis, MO) and 100
µg/ml streptomycin (Sigma-Aldrich) at 37C° in a humidified CO2 incubator.
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3.2.3. Intraductal Implantation of 4T1-Luc2-RFP Cells
Before implantation, 4T1-Luc2-RFP cells were allowed to grow for two days. Cells
from the second passage were collected, counted, and resuspended in sterile PBS at a 106
cells/ml concentration. Mice were anesthetized using isoflurane. 5 µl of cell suspension
(containing 5000 4T1-Luc2-RFP cells) was implanted intraductally into the left thoracic
mammary glands, for the first group, or right thoracic mammary glands, for the second
group, of anesthetized mice using a previously described method12, but without surgically
opening the mouse. Briefly, a Hamilton syringe with a 30-gauge blunt-ended 0.5-inch
needle was used for the intraductal implantation. The mice were anesthetized and placed
under a dissecting microscope. The teat of the thoracic gland was snipped and the needle
was inserted directly into the mammary duct through the opening of the teat.
3.2.4. Monitoring Tumor Growth
After 4T1-Luc2-RFP intraductal tumors became palpable, tumor volume was
monitored for each group (left versus right) by: (1) external caliper measurements; tumor
volume was measured semi-weekly using digital calipers (tumor volume = (length *
width2)/ 2).
(2) Bioluminescence imaging; mice were imaged weekly using IVIS Lumina system
(PerkinElmer) as previously described (107). Briefly, D-Luciferase (10 µg/gram of body
weight) was injected intraperitoneally (IP). Images were acquired 10 minutes following
the D-Luciferase injection. Live imaging software was used to quantify photons emitted
by the tumor cells.
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3.2.5. Monitoring Body Weight and End Point Tumor Mass
Body weight of left versus right injected mice groups was monitored weekly using
a Scout Pro SP202 scale. At the experimental end point, left versus right primary tumors
were harvested and weighed using an APX-60 (Denver Instrument) scale.
3.2.6. Tumor Histopathology and Image Collection
Trichrome staining of paraffin embedded tissue was used for histological
examination (local invasiveness, encapsulation, collagen deposition and fibrosis) of the
left versus right primary tumors. The stained sections were examined and photographed
using a Nikon Eclipse Ni microscope.
3.2.7. Immunofluorescence Staining of Ki-67
4 µm sections of 4% paraformaldehyde fixed and paraffin embedded tumors
tissue were used for Ki-67 immunofluorescence staining using the manufacturer’s
protocol (Bio-Legend). Briefly, sections were deparaffinized in xylene and rehydrated
through graded ethanol series. Antigen retrieval was performed on slides heated in
10mM citrate buffer (pH = 6.0) in water bath for 30 min at 95C°. After blocking with 5%
goat serum for 30 minutes, Ki-67 (monoclonal rat anti-mouse) primary antibody (BioLegend) was added in concentration of (5 µg/ml). Slides were incubated for one hour at
room temperature (RT) followed by overnight incubation at 4C°. After washing, slides
were incubated with secondary antibody (1µg/ml - Alexa Fluor 488) for two hours at RT.
DAPI staining was added for nuclear labeling followed by mounting media and coverslips.
Slides were photographed using a Nikon Eclipse Ni microscope. Five different field of view
were imaged and analyzed for each tumor sample. The percentage of Ki-67 was calculated
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for each tumor sample by counting the number of Ki-67 positive cells dividing the number
of the live cells DAPI positive cells.
3.2.8. Quantification of Micro-Metastasis of Left versus Right Groups
Micro-metastases were quantified in different organs using colony assay as
described previously (129). Briefly, at five weeks post tumor cell injection, lungs, brain,
liver, and spleen were harvested and transferred to 6-well plates containing 1 X HBSS
(Hank’s balanced salt solution- Gibco) to remove any remaining blood. Each organ was
minced using sterile scalpels into less than 1 mm3 pieces. For lungs and brain, the minced
tissues were mixed with 2.5 ml collagenase IV/ elastase cocktail (5 mg collagenase IV in
2.5 ml HBSS and 30 units elastase) for enzyme digestion. The lung samples were incubated
at 4°C for 75 minutes while the brain samples were incubated at 37°C for 120 minutes.
For liver and spleen, the minced tissues were mixed with 2.5 ml collagenase type I cocktail
(5 mg collagenase I in 2.5 ml HBSS) for enzyme digestion and incubated at 37°C for 30
minutes.
After completion of the enzyme digestion, samples were filtered through 70 µm
nylon cell strainers, and the suspension was centrifuged for 5 minutes at 1500 rpm at
room temperature. After washing the pellets with HBSS, the pellets were resuspended in
10 ml culture medium (IMDM supplemented with 10 % FBS, 1 X antibiotic-antimycoticLife Technology, and 60 µM 6-thioguanine- sigma) and plated onto 10 cm tissue culture
dishes and incubated in 37°C tissue culture incubator, 5% CO2 for 11 days.
To count the metastatic colonies, the culture medium was discarded and the
colonies were fixed by adding 5 ml methanol to each plate and incubated at RT for 5 min.
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After rinsing the colonies with 5 ml distilled water, 5 ml of 0.03 % methylene blue solution
was added to each plate to stain the colonies. After rinsing the colonies with 5 ml distilled
water, the plates were allowed to dry before counting the colonies.
3.2.9. Quantification of Macro-Metastasis of Left versus Right Groups
To study macro-metastasis in distant organs such as lungs, brain, liver, and spleen
of left and right tumors groups, standard hematoxylin and eosin staining was performed.
25 sections were stained for each organ, each set of 5 sections was collected from
different levels within the organ. The stained sections were examined and photographed
using a Nikon Eclipse Ni microscope.
3.2.10. Isolating Tumor 4T1-Luc2-RFP Cells from Left versus Right Tumors and RNA
Isolation
4T1-Luc2-RFP cells were isolated from the 4T1 intraductal tumors by RFP
expression. Left and right tumors were harvested at day 24 post tumor cells injection and
processed for single cell suspension as described in chapter 2 section (2.2.7). RFP positive
4T1 cells were sorted using fluorescence-activated cells sorting (FACS). The sorted RFP+
4T1 cells from left or right tumors were collected in tubes containing Qiazol lysis reagent
and processed for RNA extraction using Qiagen mini kit following the manufacture’s
protocol.
3.2.11. RNA-Seq Analysis
Three independent RNA preparation from 4T1-Luc2-RFP cultured and FACS 4T1Luc2-RFP cells were used to conduct RNA sequencing analysis. The RNA-Seq libraries were
created using the TruSeq RNA Sample Prep kit. Libraries were sequenced on HiSeq 2500,
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following the manufacturer’s protocols. The mapping of the processed reads was
performed by using HISAT with mm10 reference genome; reads were counted by using
HTSeq (108, 109). Genes showing less than 10 counts on average across all samples were
removed, resulting in 14,027. The remaining values were normalized with TMM
normalization method and then transformed with voom transformation (110, 111).
3.2.12. Isolating Tumor-Associated Macrophages from Left versus Right Tumors
Tumors were harvested at day 24 post tumor cells injection and processed for
single cell suspension. Briefly, tumor tissue (600-800 mg) were dissociated: first
mechanically using sterile scalpels into less than 1mm3 pieces and then enzymatically
using a mix of collagenase IV (4 mg/mL), Hyaluronidase (1 U/mL), and DNase I (20 µg/mL)
(Sigma-Aldrich St. Louis, MO) in 5 mL of serum-free RPMI medium for 1 hour at 37 °C
shaking water bath. After washing from the enzyme mix, pellets were resuspended in 5
mL RBC lysis buffer for 3 min at room temperature. Then, the cell suspension was passed
through a 70 µm cell strainer to obtain the single cell suspension. Cells then were counted
and stained with F4/80 anti-body (FITCI- Bio Legend) and incubated at 4°C for 45 min.
After washing, the F4/80+ cells were then isolated using EasySepTM Mouse FITCI Positive
Selection Kit (Stem Cell Technologies, Vancouver, BC) as previously described (141).
3.2.13. Quantitative Real Time PCR (Qpcr)
The isolated macrophages from left versus 4T1 tumors were lysed with Qiazol and
RNA was extracted using Qiagen mini kit following the manufacture’s protocol. Then,
cDNA was made from 1 µg of RNA using iScript cDNA Synthesis Kit (Bio-Rad Life Science,
Hercules, CA).
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SYBR Green-based RT-PCR was preformed to determine left versus right tumorassociated macrophage polarization using the primers listed in table 3.1. Real-time PCR
miner was used to calculate CT value (142). Fold changes were determined by delta-delta
CT relative to GAPDH mRNA. Then data was normalized to the left group.
3.2.14. Copy Number Alteration and Mutated Genes
We used the genomic analysis of Copy Number Alteration (CNA) and mutated
genes that are publically available in cBioPortal (http://www.cbioportal.org/) to test if
human breast tumors exhibit left-right differences in genomic profiles (143). We used two
databases in this analysis: (1) the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) which has a cohort of 2,510 breast cancer patients. (2) The
Cancer Genome Atlas (TCGA) which has a cohort of 1,098 breast cancer patients. First, we
were able to use the annotation in the clinical data to separate 203 (METABRC) and 95
(TCGA) triple negative breast cancer patients (TNBC) based on their receptors status (ER, RP-, and HER2-). TNBC patients were further separated into left and right groups based
on the sidedness annotation. Genes presented in less than 10% of TNBC tumors were
excluded. The frequency of Genes CNA and mutated genes were compared in left versus
right TNBC tumors for significant differences.
3.2.15. Mouse to Human Comparative Genomic Analysis:
We used a large cohort of breast cancer patients from The Cancer Genome Atlas
(TCGA) database (n=982) (https://cancergenome.nih.gov/) to test the genes differentially
expressed between left and right mouse mammary tumors (tables 3.2, 3.3) are also
regulated in human breast tumors. The differentially expressed genes were used to
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perform Gene Set Enrichment Analysis (GSEA) (144, 145) to examine whether they are
significantly enriched in left versus right human breast tumors.
A large cohort of 1,593 breast cancer patients from multiple studies available
through

the

Gene

Expression

Omnibus

GEO

database

(http://www.ncbi.nlm.nih.gov/geo/) was used to test the association between molecular
left-right differences of mouse mammary tumors and patient survival. The compilation of
the cohort is described by Dvorkin-Gheva and Hassell (146). Since we are using triple
negative breast cancer cell line (4T1-Luc2-RFP) in mouse study, we used triple negative
breast cancer TNBC patients. The Status of ER, PR, and HER2 receptors was determined
by using predictive signatures(147). We used the disease-free survival as the clinical end
point in our study; however, when disease-free survival was not available, we
alternatively used overall survival as the clinical end point. The expression values for each
gene were standardized so the mean was set to 0 and the standard deviation was set to
1. Signature scores were calculated for each patients as descried previously (148, 149),
where positive scores were considered to indicate that a tumor had ‘right-sided’ gene
expression and negative scores were considered to indicate that a tumor had ‘left-sided’
gene expression.
3.2.16. Statistical Analysis
For all the experiments, the data was represented as the mean ± standard error
of the mean (SEM). To determine the significant differences between left versus right
tumor groups, we used two-tailed Student’s t-test using GraphPad Prism software. We
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also used two-tailed proportion tests when comparing the percentages between left and
right groups.
For RNA-Seq analysis, Limma package was used to examine differential expression
between the groups of interest, obtained p-value were corrected with BH correction for
multiple testing and genes exhibiting corrected p-value < 0.05 were considered to be
significant and were used in further analysis (112, 113). BINGO plugin in Cytoscape
environment was used to examine Gene Ontology (GO) Biological processes (114, 115).
Hierarchical clustering was performed by using gplots package (https://cran.rproject.org/web/packages/gplots/index.html).
For the survival analysis we used Log-rank available in GraphPad Prism test to
determine the significant differences between left-sided and right-sided groups(150).

3.3. Results
3.3.1. Left versus Right Mammary microenvironments Promote Equivalent Tumor
Growth but Differentially Affect Mice Body Weight
In order to determine if left versus right microenvironments effect 4T1 tumor take
and tumor growth rate differently, we generated 4T1-Luc2-RFP tumors in either the left
or the right mammary epithelial microenvironment of the thoracic glands. Using an
intraductal injection (Fig. 3.1 a), we injected the same number of 4T1-Luc2-RFP cells from
the same passage at the same day and time into either the left or the right thoracic
mammary glands of adult female BALB/c mice. After 7-10 days past intraductal injection,
4T1-Luc2-RFP cells give rise to palpable tumors with 100% primary tumor take for both
left and right injected groups.
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After the left and right tumors became palpable, two standard methods were used
to monitor tumor growth over the experimental time: First, a digital caliper was used to
measure tumor volume semi-weekly (Fig. 3.1 b) which showed that left versus right
tumors have similar volume over the experimental time. Second, measuring the luciferase
activity of 4T1-Luc2-RFP cells allows for in vivo monitoring of tumor growth using an in
vivo imaging system (IVIS). The luminescence data of 4T1-Luc2-RFP left versus right
tumors showed a similar increase in tumor mass over the five weeks of the experimental
time (Fig. 3.1 c-d). These results indicate that left versus right mammary
microenvironments similarly support tumor take and tumor growth rate.
We also monitored mouse body weight over the experimental time. Our results
show that mice bearing right tumors reduced their body weight over the experimental
time compared to mice bearing left tumors (Fig. 3.1 e), even though the end point tumor
mass was equivalent for both groups (Fig. 3.1 f). This data indicates that despite the
equivalent growth rate and mass, right tumors have a significant effect on mice body
weight compared to left tumors. This suggests the onset of cachexia in the right tumor
group which associated with more advanced cancer and metastatic development (151153).
3.3.2. Right Mammary Microenvironment Promotes More Aggressive Histopathological
Features of 4T1 Tumors
To investigate the differences in left versus right 4T1 tumors that cause the
different effects in body weight, several histopathological features were examined (Fig.
3.2). Upon the end point, trichrome stained sections from left and right 4T1 tumors were
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examined for smooth muscle invasion, encapsulation, and collagen deposition and
fibrosis. Our results show that smooth muscle invasion presents in right side tumors with
significantly more frequency (83%) compared to 33% in left side tumors (Fig. 3.3 A-1, B1). The results also show that there were no significant differences in the presence of
encapsulation in left versus right tumors (Fig. 3.3 A-2, B-2). Moreover, the
histopathological analysis shows that 100% of right side tumors show collagen deposition
and fibrosis compared to only 17% of left side tumors (Fig. 3.3 A-3, B-3). Higher frequency
of muscle invasion and collagen deposition and fibrosis are known to be associated with
more aggressive cancers (68, 103, 154). These results indicate that the right mammary
microenvironment promotes more aggressive tumors compared to the left mammary
microenvironment.
3.3.3. Right Mammary Tumors are More Proliferative than Left Tumors
For further investigation about the histopathological differences, we examined
the proliferation rates of left versus right tumors using Ki-67 expression. The percentage
of Ki-67 positive cells were compared for left versus right tumors. Our results show that
right tumors demonstrate significantly higher level of Ki-67 expression compared to left
tumors (Fig. 3.3). This data indicates more proliferative activity of right tumors which
matches what has been reported about Ki-67 expression in human breast cancer (155).
3.3.4. Right Mammary microenvironment Promotes More Metastasis Compared to Left
Mammary Microenvironment
To assess the metastatic behavior of left versus right 4T1-Luc2-RFP tumors, we
examined the lungs of left versus right tumor groups for the presence of lung micro and
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macro metastasis. We used the colony assay to determine lung micro-metastasis in left
versus right groups (n=7 per group). Our results show that 100% of the mice with right
side tumors have micro-metastases compared to 57% in the left tumor group (Fig 3.4 a).
Then we examined hematoxylin and eosin stained lung sections to determine the
presence of lung macro-metastasis in left versus right tumor groups (n=15 per group). Our
data shows that 87% of mice with right tumors have lung macro-metastasis while only
40% of the left tumor group have macro-metastasis at three weeks post tumor cells
injection (Fig. 3.4 b). Moreover, the number of lung macro-metastasis was significantly
higher in the right tumor group compared to the left tumor group (Fig. 3.4 c-e).
Our results also show that at five weeks post tumor cells injection, there were no
significant differences in the percentage of mice with macro-metastasis in left versus right
tumors group (Fig. 3.4 f). However, the number of lung lesions was significantly higher in
the right tumor group compared to the left tumor group (Fig. 3.4 g).
Altogether, the metastasis data (micro, macro-metastasis, and the number of
lesions) shows that the right tumors are significantly more metastatic than the left
tumors. This indicates that right mammary microenvironment promotes more aggressive
4T1-Luc2-RFP tumors, consistent with more aggressive tumor progression in right-side
breast cancer patients (90, 91).
3.3.5. Left versus Right Mammary microenvironments Promote Differences in Tumor
Cells Transcriptome
To determine the mechanisms of right tumors being more aggressive than the left
tumors, we conducted a comparative analysis of global gene expression changes in cancer
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cells isolated from left versus right tumors. To do that, we isolated 4T1-Luc2-RFP cells
from left versus right tumors using fluorescence activated cells sorting (FACS), taking
advantage of the RFP expression, as shown in the schematic (Fig. 3.5 a). Then, we
conducted RNA sequencing for the isolated 4T1-Luc2-RFP cells and compared the left
versus right gene expression profiles. RNA-Seq analysis yielded of 177 differentially
expressed genes (24 left upregulated genes listed in tables 3.2, and 153 right upregulated
genes listed in table 3.3) in the isolated 4T1-Luc2-RFP cells from left tumors compared to
right tumors, as shown in the heat map (Fig. 3.5 b). Most of upregulated genes in right
isolated 4T1-Luc2-RFP cells are associated with more advanced cancer and metastatic
behavior such as ADAM, COL, HOX genes family. While the upregulated genes in left
isolated 4T1-Luc2-RFP cells are associated with anti-tumor immune processes. These
results indicate for the first time that left versus right mammary microenvironments
(soils) promote differential gene expression of cancer cells with more aggressive genes in
the right side.
Then, we subjected the 177 gens to pathway analysis, which showed significantly
different pathways that affected in left versus right isolated 4T1-Luc2-RFP cells (Fig. 3.5
c). While the main affected pathway in the left tumors is associated with immune
processes, the pathways affected on the right tumors are associated with more aggressive
tumors, including pathways that regulate Wnt signaling and ECM remodeling (68, 131,
156). This data is consistent with what has been described that the pathways affected by
right mammary glands are associated with oncogenesis (92).
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3.3.6. Right Mammary Tumors Promote More M2-Like Macrophages
Our previous results indicate that right mammary microenvironment promotes
more aggressive tumor progression compared to the left mammary microenvironment.
We hypothesize that tumor-associated macrophages (TAMs) (number and/or phenotype)
are part of the mechanism to promote more metastasis in right tumors. To determine the
difference in TAMs content in left versus right tumors, we first quantified the total
number of TAMs (F4/80 positive cells) in left versus right 4T1-Luc2-RFP tumors. Our
results show that the total number of TAMs is equivalent in left versus right 4T1-Luc2-RFP
tumors (Fig. 3.6 a). Then, we examined TAMs phenotype (M1 versus M2) by gene
expression using RT-qPCR. Our data shows that M2 TAMs genes expression were
significantly elevated in TAMs isolated from right 4T1-Luc2-RFP tumors compared to
TAMs isolated from left 4T1-Luc2-RFP tumors (Fig. 3.6 b, c).
This data suggests that promoting more M2-like macrophages increases the
metastatic activity of right-side tumors, consistent with what has been reported for the
role of M2 macrophages in promoting more aggressive and metastatic breast cancer(51,
52, 157).
3.3.7. Human Breast Cancer Tumors Exhibit Left-Right Differences in Gene Copy Number
Alteration and Mutated Genes.
To determine if human TNBC tumors exhibit left-right differences in genomic
profiles, the frequency of genes CNA and mutated genes were compared in left versus
right TNBC tumors. Our results show that there are significant differences in the
frequency of genes CNA (amplification) between left and right TNBC tumors (table 3.4).
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Some of the genes that amplified more frequently in the right TNBC tumors are known to
regulate tumorigenesis and immunosuppressive such as RSPO2, HOOK, and PRDM1 (158160). While genes that amplified more frequently in left TNBC tumors are found to be
associated with anti-tumor immunity such as KLF6, and CD22 (161, 162). Our results also
show that significant differences in the frequency of mutated genes in left versus right
tumors (table 3.5).
3.3.8. Right mammary tumors’ upregulated genes are associated with poorer breast
cancer patients’ survival
To determine if the left-right differences that we found in mouse mammary
tumors are clinically relevant, the genes identified in our RNA-Seq analysis (tables 3.2, and
3.3) were evaluated using the publically available databases TCGA and GEO. Because the
TCGA database has available annotation of tumors location, left or right breast, we first
use TCGA database to evaluate if left and right human breast tumors exhibit biological
association with left-right mouse mammary tumors. To do that, we analyzed the genes
differentially expressed between the left and the right mouse tumors shown in table 3.2
and table 3.3 respectively using Gene Set Enrichment Analysis GSEA for biological
association. Out of 177 differentially expressed genes, 150 genes were found to be
represented in the TCGA dataset. These genes were used for the GSEA analysis. The
enrichment plot (Fig. 3.7 a) shows the distribution of genes up-regulated in right mouse
tumors across right and left human tumors. The GSEA results show that genes
upregulated in mouse mammary tumours originating from the right side are enriched in
human breast tumours originating from the right side. We also found that the genes up-
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regulated in left mouse tumors did not show significant enrichment in left human tumors.
These results suggest the biological similarities between mouse right mammary tumors
and the human right breast tumors.
For further investigation for the clinical relevance of the biological association
between mouse mammary tumors and human breast tumors, the left versus right genes
identified in our RNA-Seq analysis were evaluated in GEO data sets in which patient
outcomes is known. We used TNBC patients in this analysis. Because GEO datasets lack
the sidedness of breast tumor location, we used the left versus right profiles identified in
the mouse mammary tumors RNA-Seq (tables 3.2, and 3.3) to assign patients into leftsided (305) or right-sided (58) breast tumors. At 5 years time point, our results show
significant differences in patient’s outcomes between left-sided and right-sided groups
(Fig 3.7 b). Our results show that the left versus right profiles identified in the mouse
mammary tumors RNA-Seq are significantly linked to breast cancer patient survival rates,
and demonstrate that right-sided gene expression is associated with poorer survival.

3.4. Discussion
Despite their equivalent growth rate and end point mass, our results demonstrate
for the first time that left and right mammary tumors differ in their progression and
metastatic behavior. In this study, we incubated the same number of the same cancer
cells in two molecularly different mammary microenvironments (left versus right) (92).
Our result showed equivalent growth rates for left versus right tumors. However, the
body weight of mice bearing right tumors was significantly reduced over the experimental
time. This data suggests the onset of cachexia which associated with aggressive growth
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and metastatic potential of right tumors (151-153). To investigate the differences in left
versus right tumors, we examined the histopathological features of left versus right
tumors. Right tumors possess more advanced features such as more muscle invasion and
collagen deposition, and higher proliferative rate (Ki-67 expression) compared to the left
tumors. This data is consistent with a study showed that right-sided breast cancer have
higher proliferative rate compared with left breast cancer (155). Our results further
showed that right tumors are more metastatic, more lung cancer incidence with more
lung lesions per mouse, consistent with more metastatic development reported for rightsided breast cancers (90).
Our results of RNA-Seq analysis show significantly different expression levels (upregulated or down-regulated) of 177 genes in left versus right isolated tumor cells. Most
of the genes that up-regulated in 4T1 cells isolated from right tumors are associated with
more aggressive disease progression, such as MMPs, several genes from the COL family,
some Hox family genes, and Wnt (68, 132, 156, 163). In contrast, genes that upregulated
in 4T1 cells isolated from left tumors are associated with anti-tumor immunity, such as
CCL12, CXCL13, and CD226 (164-166). Moreover, the pathway analysis shows significantly
different pathways that are affected in left versus right tumors. These results
demonstrate for the first time that left versus right mammary glands alter cancer cells’
gene expression differently. Our results also indicate that right mammary
microenvironment promotes more aggressive tumor cells compared to the left side.
Moreover, our data of mouse left versus right differential genes were associated with
different survival rates with right genes linked to poorer survival rates. These results are
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consistent with the Robichaux et. al. study which showed that genes elevated in right
normal mammary glands are correlated with more aggressive disease progression and
poorer patients’ survival rate(92). Furthermore, as part of the mechanism for this, our
data indicates that the right mammary microenvironment promotes more M2-like
macrophages which are known to support cancer progression and metastasis (50, 157).
Taken together the data presented here is the first to show, using a functional
study, that left and right mammary microenvironments differentially support tumor
progression and metastasis. Our findings highlight the importance of laterality as a
parameter to be considered not only in the perspective of modeling human breast cancer
but also in clinical analysis of breast cancer patients. This study also has broader
implications on the importance of investigating laterality in other paired organs during
cancer progression and metastasis.
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Table 3.1: RT-qPCR primers

Gene

Forward

Reverse

GAPDH

CAGCAAGGACACTGAGCAAGA

TATGGGGGTCTGGGATGGAAA

IL-10

GGACAACATACTGCTAACCGAC

TGGATCATTTCCGATAAGGCTTG

Arg-1

TGAACAGGCTGTATTAGCCAACA

AGCACCCTCAACCCAAAGTG
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Table 3.2: Upregulated genes in left FACS isolated 4T1-Luc2-RFP cells.

Left-side upregulated genes

Fold change

Glyctk

1.5

Sesn1

1.53

Gm4013

1.56

C1qa

1.79

Nr3c2

1.84

Cd200r4

1.97

Mag

1.99

Slc15a2

2.03

Lrfn1

2.05

Lefty1

2.06

Crym

2.24

Gm13710

2.31

Gpr82

2.33

Ccl12

2.47

Aoah

2.62

Omp

2.63

Cd226

2.67

Epor

2.94

Rab39

3.02

Gzma

3.24

Sectm1a

3.44

Gm13154

3.51

Rnase6

3.71

Cxcl13

5.76
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Table 3.3: Upregulated genes in right FACS isolated 4T1-Luc2-RFP cells.

Right-side upregulated
genes
Kctd11
LOC100504703
Kcnb1
Adam12
Pcdhga10
Ndst3
P4ha3
Lmo7
Antxr1
Col4a2
Itgb3
Ttc41
Cttnbp2
Creb3l1
Col7a1
Slit2
Egfl7
Snhg18
Col5a1
Bgn
Gpc4
C030037D09Rik
Sparc
Mecom
Oacyl
Emx2
Ccdc80
Brinp3
Cdh2
Col12a1
Crabp1
Prkd1
Kcnq3
Col5a2
Serp2
Nexn
Cthrc1

Fold
change
1.37
1.51
1.53
1.53
1.53
1.54
1.55
1.55
1.55
1.56
1.57
1.57
1.57
1.59
1.59
1.6
1.61
1.62
1.63
1.66
1.67
1.67
1.68
1.68
1.68
1.69
1.7
1.71
1.72
1.72
1.73
1.73
1.74
1.75
1.75
1.76
1.76

Right-side upregulated
genes
Gata6
Ror2
Hmx2
Hoxb2
Snai2
Ehd3
Sobp
Igfbp3
Pnpla3
Nrep
Mcam
Khdrbs3
Gria3
Fhl1
Jph2
Gcnt4
Nkd1
Tnc
Tmem47
Col6a3
Klhl30
Usp13
Cdkn2b
Myl9
Kcnmb1
Lama1
Col15a1
Stra6
Tll1
Syt5
Wnt11
Lrrc15
Mmp15
Nos3
Cldn5
Cplx2
Tmem200a
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Fold
change
2.03
2.03
2.03
2.03
2.04
2.05
2.05
2.08
2.1
2.1
2.11
2.11
2.12
2.12
2.13
2.13
2.14
2.14
2.16
2.17
2.18
2.18
2.23
2.23
2.26
2.26
2.27
2.27
2.28
2.29
2.32
2.33
2.34
2.35
2.37
2.38
2.38

Lpar4
She
Fam46b
Nid2
Prss23
Htr2a
Mmrn1
Tbx3
2810454H06Rik
Gm1141
Col6a2
Mmp9
Gpihbp1
Adamts9
Grem2
Mxra7
Cnih2
Ncam1
Rbp1
Hs6st2
Lrch2
Fam198b
Gli2
Srpx2
Chsy3
Tspan6
Fjx1
Igfbp7
Akap12
Atp8b1
Clec11a
Msx1
Kcnip4
Rnf223
Tmem204
Slc3a1
Dmd
Hoxc8
Dysf
Epha3

1.77
1.79
1.79
1.79
1.8
1.8
1.81
1.81
1.82
1.83
1.84
1.85
1.85
1.86
1.87
1.88
1.88
1.88
1.89
1.89
1.89
1.9
1.91
1.91
1.92
1.92
1.94
1.95
1.96
1.97
1.98
1.98
1.99
1.99
1.99
2
2
2.01
2.02
2.02

Emcn
AA413626
Prr9
Tagln
Hey1
Unc5c
Heyl
Meox1
Pcsk9
Slc12a3
Erg
Ptprn
Abca4
Pcdh12
Lrrc55
Slc5a5
Cspg4
Krt42
Col11a1
Mest
Plet1os
Tmem252
Gucy1a2
Hoxb7
Hoxb8
Myh11
Fmod
St8sia2
Abcb4
Ppbp
Enho
Tacr1
Kcne3
Slc8a3
Clca1
Palm2
Sox17
Clhc1
Htr1b
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2.38
2.39
2.4
2.41
2.41
2.42
2.42
2.42
2.42
2.45
2.46
2.48
2.56
2.56
2.6
2.64
2.65
2.66
2.7
2.83
2.87
2.87
2.88
2.89
2.97
3.1
3.11
3.19
3.2
3.34
3.41
3.46
3.51
3.63
3.71
3.8
3.86
3.97
4.19

Table 3.4: Copy Number Alteration CNA of left versus right
human breast tumors

Gene
KLF6
TERT
SDHA
TSHZ3
CD22
CEBPA
KMT2B
AKT3
SMYD3
FH
HEY
IL-10
RSPO2
RUNX1T1
NBN
CCND2
HOOK3
PRDM1

p-value
< 0.05
< 0.01
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.05
< 0.01

Side
Left
Left
Left
Left
Left
Left
Left
Left
Left
Left
Left
Left
Right
Right
Right
Right
Right
Right
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Table 3.5: Mutated genes of left versus right
human breast tumors.

Mutated Genes

p-value

Side

SPTA1

< 0.05

Left

SYNE1

< 0.05

Left

F5

< 0.05

Left

FAT1

< 0.05

Left

PIK3CA

< 0.05

Left

CREBBP

< 0.05

Right

KMT2D

< 0.05

Right

FLG

< 0.05

Right

FRG1

< 0.05

Right

MUC4

< 0.05

Right
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Figure 3.1: Left versus right 4T1 tumors. (A) Schematic shows the intraductal
implantation of 4T1-RFP-Luc2 cells into left (group 1) or right (group 2) thoracic glands of
adult female BALB/c mice. (B) Tumor volume was monitored every three days using digital
calipers (n=12). (C) Mice were imaged on a weekly basis by IVIS starting second week postinjection to monitor tumor growth as shown in a representative mouse. (D) Photon flux
per second (ph/sec) was measured using IVIS to monitor tumor growth (n=12). (E) Mice
body weight was monitored on a weekly basis (n=12). (F) 4T1 tumor weight was measured
upon sacrifice (n=12) (** P<0.01).
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Figure 3.2: Left versus right 4T1 tumor histopathology. Trichrome staining of left (A) and
right (B) 4T1 primary tumor sections (10X) illustrating various histopathological features
that differ between left and right 4T1 tumors. A representative image shows smooth
muscle (S.M.) and the frequency of smooth muscle invasion (n=6) in left (A-1) and right
(B-1) 4T1 tumors. A representative image shows the present of encapsulation (black
bracket) and its frequency (n=6) in left (A-2) and right (B-2) 4T1 tumors. A representative
image shows collagen deposition (black arrow) and its frequency (n=6) in left (A-3) and
right (B-3) 4T1 tumors.
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Figure 3.3: Ki-67 expression in left versus right 4T1 tumors. (A) Representative images of
immunofluorescence staining of ki-67 expression in 4T1-Luc2-RFP primary tumor sections
(arrows head) (B) The percentage of ki-76 expression in left versus right tumors (n=10)
(scale bar= 100µm) (* P<0.05).
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Figure 3.4: Lung micro and macro metastasis of left versus right 4T1 tumor groups. Upon
sacrifice at three weeks post injection, number of mice with presence of lung micrometastasis using colony assay (A) and with presence of lung macro-metastasis were
quantified using histological analysis three weeks post injection (B). Representative
images of lung macro-metastasis of left-tumor bearing (C) and right-tumor bearing (D)
groups. Number of lung lesions in left-tumor bearing versus right-tumor bearing groups
at three weeks post injection (E). Number of mice with presence of lung macro-metastasis
at five weeks post injection (F) and the number of lung lesions at five weeks post injection
(g) (* P<0.05, ** P<0.01, *** P<0.001).

67

Figure 3.5: Distinct gene expression profiling of left versus right FACS isolated 4T1-Luc2RFP. (A) Schematic shows the experimental design to isolated 4T1-RFP+ cells from left
versus right tumors. (B) A heat map displaying 177 genes that differentially expressed
after intraductal incubation of 4T1-Luc2-RFP in left versus right microenvironment. (C)
Pathway analysis of differentially expressed genes in 4T1-Luc2-RFP post-intraductal
incubation in left (green circle) versus right (red circles) microenvironment.
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Figure 3.6: Tumor-associated macrophage (TAMs) content of left versus right 4T1
tumors. (A) Percent of TAMs (F4/80+ cells) in left versus right 4T1 tumors. (B) SYBR Greenbased RT-PCR analysis of IL-10 gene expression in TAMs isolated from left versus right 4T1
tumors and (C) Arg-1 gene expression in TAMs isolated from left versus right 4T1 tumors
(* P<0.05, ** P<0.01).
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Figure 3.7: Comparative genomic analysis of mouse L-R tumors’ FACS isolated 4T1
transcriptome with human breast tumors and the association to patients’ survival rates.
(A) Gene Set Enrichment Analysis plot shows that the genes up-regulated in the right FACS
isolated 4T1 mouse tumors are enriched in the right breast human tumors. (B) Survival
analysis of left versus right TNBC patients groups at 5 years time point.
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Chapter 4
Role of Mammary Microenvironment in Promoting Left-Right Differences
in Response to Emodin Treatment
4.1. Introduction
Despite the significant progress in therapeutic strategies, breast cancer is still the
second leading cause of cancer-related death in women worldwide (167). This is in part
because there is still no treatment available to prevent or treat metastatic development,
considered the main cause of death in breast cancer patients. Metastatic development is
highly supported by the tumor microenvironment which is made up of many different cell
types beyond tumor cells. Tumor-associated macrophages (TAMs) are the most common
immune cells present in the tumor microenvironment. TAMs, particularly those displaying
the M2 phenotype, promote tumor progression and metastasis through suppressing antitumor immunity, stimulating angiogenesis, supporting cancer stem cells, and enhancing
tumor cells migration and invasion (41, 50, 168, 169). Our data further showed that TAMs
phenotypes differ in left versus right mammary tumors’ microenvironments. Due to their
crucial role in cancer progression and metastasis, TAMs are considered a therapeutic
target for breast cancer metastasis.
There is increasing use of natural compounds and their derivatives as a source of
new therapies. A number of active compounds have been purified from traditional
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medicine, particularly Chinese traditional medicine, and have been found to have a
biological activity against disease (72, 170, 171).

Emodin is one of these natural

derivatives isolated from roots and barks of several Chinese herbs. Emodin has been
found to have anti-inflammatory properties through targeting macrophage activation (74,
172). Its ability to target macrophage activation makes emodin a potential therapy to
treat breast cancer metastasis.
Studies have shown that emodin treatment inhibits tumor growth and metastasis
through targeting macrophages. In orthotopic mouse models, emodin treatment blocks
macrophage-cancer cell interaction within the tumor microenvironment. Moreover,
emodin treatment was found to reduce M2 macrophage recruitment to the lung (84, 85).
In addition to emodin’s ability to target macrophages, emodin has a strong potential to
suppress the growth of various cancer cell lines, including breast cancer cell lines, through
modulating apoptosis and proliferative pathways (74, 173-175). Furthermore, in vitro
studies showed that emodin attenuates tumor growth by targeting cancer cells and
microenvironmental tumor support, such as angiogenesis (82, 84). Studies have also
shown that emodin can inhibit cancer stem cell self-renewal through targeting different
signaling pathways such as Notch-1, β-catenin, and STAT3 (176, 177).
Taking together TAMs’ role in developing breast cancer metastasis, emodin’s
ability to target TAMs activation and our own results of left-right differences in
metastasis, we investigated if emodin treatment differentially affects left versus right
mammary tumor metastasis. Our data showed that emodin significantly reduces the
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metastasis of right tumors through reducing TAMs content, M2-TAMs phenotype, and
cancer stem-like cells. In left tumor metastasis, emodin treatment had no effect.

4.2. Material and Methods
4.2.1. Tumor Model
Female BALB/c mice (16 weeks old) were purchased from Jackson Laboratory (Bar
Harbor, Maine). Mice were housed in the University of South Carolina Animal Research
Facility and all experiments were approved by the Institutional Animal Care and Use
Committee IACUC of the University of South Carolina according to National Institute of
Health guidelines. 4T1-Luc2-RFP cells (5000 cells/5 µl PBS) were injected intraductally, as
described in chapter 3, into either the left or right thoracic mammary glands.
4.2.2. Emodin Treatment
Tumor volume was monitored as soon as the tumors become palpable using
digital calipers every three days (tumor volume = (length * width 2)/ 2). When tumors
become 200 mm3 in volume in average (day 14 post tumor cell injection), emodin
(40mg/kg) or vehicle (2% DMSO) was injected intraperitoneally in 1 mL PBS once daily
until mice were sacrificed at day 24 post tumor cell injection.
4.2.3. Quantify Lung Metastasis
In order to quantify lung metastasis incidence and metastasis burden, lungs were
collected from mice sacrificed at day 24. Standard hematoxylin and eosin staining was
performed on lung sections. 25 lung sections per mouse were examined for the presence
of lung lesions. Lung metastasis incidence was determined by the number of mice with
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the presence of lung lesions in each group. The number of lung lesions per mouse was
used to calculate the metastasis burden.
4.2.4. Quantify Tumor-Associated Macrophages Using Flow Cytometric Analysis
4T1 tumors were collected at day 24 post tumor cell injection from the four groups
(left DMSO, left emodin, right DMSO, and right emodin) and processed to obtain a single
cell suspension as described previously (141). Briefly, using sterile scalpels, tumors were
cut into less than 1mm3 pieces and then dissociated enzymatically using a mix of
collagenase IV (4 mg/mL), Hyaluronidase (1 U/mL), and DNase I (20 µg/mL) (Sigma-Aldrich
St. Louis, MO) in 5 mL of serum-free RPMI medium for 1 hour at 37 °C shaking water bath.
After washing from the enzyme mix, pellets were resuspended in 5 mL RBC lysis buffer
for 3 min at room temperature. Then, the cell suspension was passed through a 70 µm
cell strainer to obtain the single cell suspension and resuspended in staining buffer (PBS
containing 2% FBS). Cells were then counted and stained with anti-CD45 PE-CY7 and antiF4/80 FITCI (Bio Legend) in PBS containing 2% FBS and incubated at 4°C for 45 min. Then,
the samples were washed twice with the staining buffer and analyzed by flow cytometry
using a BD FACS flow cytometer and CXP software version 2.2 (BD Biosciences, San Jose,
CA). Data was collected for 30,000 live events per sample.
4.2.5. Isolating Tumor Associated Macrophages
Tumor-associated macrophages were isolated from 4T1 tumors at day 24 post
tumor cells injection using EasySepTM Mouse FITCI Positive Selection Kit (Stem Cell
Technologies, Vancouver, BC) as previously described (141). Briefly, tumors were cut into
small pieces (1mm3) and digested using a mix of collagenase IV (4 mg/mL), Hyaluronidase
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(1 U/mL), and DNase I (20 µg/mL) (Sigma-Aldrich St. Louis, MO) in 5 mL of serum-free
RPMI medium for 1 hour at 37 °C shaking water bath. After washing from the enzyme mix,
pellets were resuspended in 5 mL RBC lysis buffer for 3 min at room temperature. Then,
the cell suspension was passed through a 70 µm cell strainer to obtain the single cell
suspension and resuspended in PBS containing 2% FBS. For cell isolation, 1x107- 1x108
cells were incubated with 20µL FITCI conjugated anti-F4/80 (Bio Legend). The isolated
tumor-associated macrophages were directly resuspended in Qiazol and used for RT-PCR
analysis.
4.2.6. Quantitative Real Time PCR (qPCR)
The isolated macrophages from left versus right DMSO and emodin treated 4T1
tumors were lysed with Qiazol and RNA was extracted using Qiagen mini kit following the
manufacturer’s protocol. Then, cDNA was made from 1 µg of RNA using iScript cDNA
Synthesis Kit (Bio-Rad Life Science, Hercules, CA).
SYBR Green-based RT-PCR was preformed to determine the effect of emodin
treatment on left versus right tumor-associated macrophage polarization using the
primers listed in Table 1, Chapter 3. Real-time PCR miner was used to calculate CT value
(142). Fold changes were determined by delta-delta CT relative to GAPDH mRNA. Then
data was normalized to the left group.
4.2.7. Tumor-Sphere Culture for Left versus Right Tumors
Left versus right DMSO and emodin treated tumors were harvested at 24 days
post tumor cell injection. Tumors were mechanically dissociated into less than 1mm3
pieces using sterile scalpels, then enzymatically dissociated in Leibovitz’s L-15 medium
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without phenol red (Invitrogen), 1.5 mg/ml trypsin (Invitrogen), and 3 mg/ml collagenase
I (Invitrogen) at 37°C for 60 min. Samples were then processed to single cell suspension
as described previously (178).
Cells were then counted and plated on ultra-low-adherence 96 plates (Corning) at
300 cells/well in 300 µL tumor-sphere medium (serum-free and phenol red free DMEM
media (Gibco) supplemented with 1X B-27 (Gibco), 20 ng/ml basic fibroblast growth factor
(bFGF, Invitrogen), and 20 ng/ml Epidermal growth factor EGF (Invitrogen). Primary
tumor-spheres were counted and imaged 10 days after plating. Sphere forming efficiency
(SFE) was calculated by dividing the number of the spheres by the number of plated cells
per well multiplied by 100. Primary tumor-spheres then were collected and dissociated
into single cell suspension and re-suspended in new tumor-sphere medium and plated on
new ultra-low-adherence 96 plates. Secondary tumor-spheres were counted 10 days after
plating and self-renewal was calculated by dividing the number of secondary spheres on
the number of the primary spheres in each well and multiplied by 100%, as described
previously (179).
4.2.8. Statistical Analysis
For all the experiments, the data was represented as the mean ± standard error
of the mean (SEM). One-way ANOVA followed by Tukey multiple comparison test were
used to determine the significant differences among the four groups (left DMSO, left
emodin, right DMSO, and right emodin). All statistical analyses were performed using
GraphPad Prism software.
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4.3. Results
4.3.1. Emodin Reduces Lung Metastasis in Mice Bearing Right-Side 4T1 Tumors
To investigate whether left and right mammary tumor microenvironments have a
different response to emodin treatment, which is known to reduce breast cancer lung
metastasis (85, 173), we quantified lung metastasis incidence and burden in left versus
right emodin treated tumors compared to the control. We first generated 4T1 tumors
intraductally into either left or right thoracic glands (26 mice per group). After tumors
became palpable, tumor growth was monitored every three days and when tumor
volume reached 200 mm3 in average (day 14 post tumor cell injection), left and right
tumor bearing mice were randomly divided further into four groups (left control, left
emodin, right control, and right emodin) with 13 mice in each group. Emodin (40 mg/kg)
or control (2% DMSO) was injected intraperitoneally in 1 mL PBS once daily until mice
were sacrificed at day 24 post tumor cell injection. Then, hematoxylin and eosin stained
lung sections (25 lung sections per mouse) were examined for the presence and the
number of lung lesions in the four groups (left control, left emodin, right control, and right
emodin).
To assess if emodin treatment differentially reduces lung metastasis incidence in
left versus right groups, the number of mice with the presence of lung lesions was
quantified in left versus right emodin treated groups compared to the controls.
Interestingly, our results showed that emodin treatment significantly reduces lung
metastasis incidence in mice bearing right tumors to 46% compared to control group 92%
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with lung metastasis. Our results also show that emodin treatment has no effect on lung
metastasis incidence of mice bearing left tumors 46% compared to control group 42%
with lung metastasis (Fig. 4.1 a).
We also examined if emodin treatment differentially reduces the metastatic
burden in left versus right tumor bearing mice compared to the controls by quantified the
number of lung lesions per mouse in all the four groups (left control, left emodin, right
control, and right emodin). Our results show that in addition to the baseline significant
left-right differences in control groups, emodin treatment significantly reduces the
number of lung lesions in mice bearing right tumors when compared to the right control
group. Emodin treatment has no significant effect on the number of lung lesions in mice
bearing left tumors when compared to the left control group (Fig. 4.1 b). Our data also
showed that emodin treatment does not affect tumor growth (Fig. 4.1 c) and tumor end
point mass (Fig. 4.1 d) in left and right tumors bearing mice compared to the control
groups. Emodin treatment has been reported to reduce breast cancer lung metastasis in
different mouse models (85). However, this is the first study to investigate the left-right
differences in response to emodin treatment.
Our results indicate that emodin treatment was able to reduce lung metastasis
incidence and burden in right tumor bearing mice but not in left tumor bearing mice. Also,
our results show that reducing metastasis is not a result of inhibiting the primary tumor
growth or tumor end point mass. This indicates that emodin has the ability to reduce right
microenvironmental support of metastatic development but has no effect on left
microenvironmental support.
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4.3.2. Emodin Treatment Alters Tumors-Associated Macrophages Content in Right 4T1
Tumors
Our results, in chapter 3, indicate that the right mammary microenvironment
promotes more M2 TAMs which then support more metastatic behavior for right 4T1
tumors compared to left 4T1 tumors. We hypothesize that TAMs (number and/or
phenotype) are part of the mechanism by which emodin reduces lung metastasis in the
right tumor group. To determine the difference in TAMs content in left versus right
emodin treated tumors, we first quantified the total number of TAMs (F4/80+ cells) in left
versus right 4T1 tumors treated with emodin compared to the controls using flow
cytometric analysis. Our results show that emodin treatment reduces TAMs percentage
in right 4T1 tumors compared to the control (Fig. 4.2 a).
Then, we examined M1 versus M2 gene expression using qRT-PCR of TAMs
isolated from emodin treated and control left versus right 4T1 tumors. Our data shows
that in addition to the left versus right base line differences, M2 TAMs genes expression
were significantly reduced in TAMs isolated from right emodin treated 4T1 tumors
compared to TAMs isolated from left emodin treated 4T1 tumors (Fig. 4.2 b,c).
This data suggests that emodin’s ability to reduce right tumor metastasis is modulated by
reducing M2 TAMs in right tumors, consistent with what has been reported for emodin’s
ability to target macrophages in the mammary tumor microenvironment (84).
4.3.3. Emodin Treatment Reduces Cancer Stem Cells Population in Right 4T1 Tumors

79

Given the important role cancer stem cells play in metastasis (180, 181), we
hypothesize that emodin treatment differentially effects the cancer stem cell population
in left versus right 4T1 tumors. To test this hypothesis, sphere forming efficiency (SFE),
number of secondary spheres, and self-renewal were quantified for left versus right
emodin treated 4T1 tumors compared to the controls. Our results show that in addition
to base line differences in SFE in left versus right controls 4T1 tumors, right emodin
treated 4T1 tumors have significantly lower SFE compare to right control 4T1 tumors.
Emodin treatment has no effect on SFE of left 4T1 tumors (Fig. 4.3 a, b). To determine
the effect of emodin treatment on the self-renewal properties of cancer stem cells,
secondary spheres and self-renewal ability were quantified. Our results show a significant
reduction in the number of secondary spheres of right 4T1 emodin treated tumors but
not the self-renewal compared to the controls (Fig. 4.3 c, d). No effect was found on SFE,
number of secondary sphere, and self-renewal of left emodin treated 4T1 tumors
compare to the left control 4T1 tumors (Fig. 4.3 b-d).
Taken together, our results indicate that emodin treatment reduces cancer stem
cell content in right 4T1 tumors which then reduces the metastatic potential of right 4T1
tumors. This result is consistent with what has been reported for emodin’s ability to target
cancer stem cells (176, 177). Moreover, our results also show that emodin has no effect
on cancer stem cell content in left 4T1 tumors.

4.4. Discussion
Microarray analysis demonstrated that mammary glands exhibit left-right
differences in gene expression, including genes associated with therapeutic response
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(92). However, no existent study has determined if left versus right mammary tumors
have different response to treatment. Here, we use mouse models to show for the first
time that left and right mammary tumors respond differentially to emodin treatment.
Emodin is a natural compound isolated from several Chinese herbs that has been reported
to have anti-cancer activity in different cancers including breast cancer (81, 84, 182, 183).
Our data demonstrates that emodin significantly inhibited lung metastasis of right
4T1 tumors through modulating the tumors’ microenvironmental support. Emodin
significantly reduces TAMs content and M2 TAMs gene expression in right 4T1 tumors.
Increase evidence shows the critical role of TAMs in supporting metastasis through the
promotion of invasion, migration, intravasation, and ECM remodeling (62, 65, 66). Our
data here indicates that targeting TAMs content and polarization is part of emodin’s
mechanisms to inhibit lung metastasis in right mammary tumors.
Our results also show emodin’s ability to reduce primary and secondary
tumorsphere formation in right 4T1 tumors. This data suggests that emodin reduces
cancer stem cells content in right mammary tumors which then inhibits metastatic
development. Studies have shown that emodin can target cancer stem cells directly
through Notch-1, β-catenin, and STAT3 signaling pathways (177). This data also suggests
the indirect effect of emodin on cancer stem cells through its effect on TAMs which then
effect cancer stem cells content in right mammary tumors. It has been reported that
TAMs play a crucial role in regulating cancer stem cells in different cancers (169, 184). Our
data indicates that emodin reduces lung metastasis in right 4T1 tumors group through
targeting TAMs and cancer stem cells in tumor microenvironment. Our results also
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indicate that emodin has no effect on left 4T1 tumors metastasis, TAMs content, and
cancer stem cells content.
Our data of left-right differences in mammary tumors therapeutic response
suggests that women with breast cancer might have different responses to therapies
based on their tumor situs. This data therefore also highlights the importance of laterality
in testing anti-cancer drug sensitivity in mouse models as well as in clinical trials.
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Figure 4.1: Emodin inhibits lung metastasis incidence and burden in mice bearing right
4T1 tumors. (A) Upon sacrifice, number of mice with presence of lung metastasis by
histological analysis were quantified for left versus right 4T1 DMSO and emodin treated
groups. (B) Number of lung lesions in left versus right 4T1 DMSO and emodin treated
groups. (C) Tumor volume of Left versus right 4T1 DMSO and emodin treated groups was
monitored every three days using digital calipers (n=13). (D) Left versus right 4T1 DMSO
and emodin treated tumor weight was measured upon sacrifice (n=13) (** p<0.01) (***
p<0.001).
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Figure 4.2.: Emodin treatment decreases tumor-associated macrophages total number
and M2 phenotype. (A) F4/80+ cells percentage in left versus right 4T1 DMSO and Emodin
treated tumors. (B) SYBR Green-based RT-PCR analysis of IL-10 gene expression in TAMs
isolated from left versus right 4T1 DMSO and Emodin treated tumors and (C) Arg-1 gene
expression in TAMs isolated from left versus right 4T1 DMSO and Emodin treated tumors
(* p<0.05) (** p<0.01) (***p<0.001).
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Figure 4.3.: Emodin quantitatively reduces cancer stem-like cells in right 4T1 tumors
compared to left 4T1 tumors. (A) Representative images of tumor spheres from left
versus right DMSO and Emodin treated groups. (B) Sphere Forming Efficiency (SFE) of
primary sphere and (C) The number of secondary spheres from left versus right DMSO
and Emodin treated 4T1 tumors shows that in addition to base line left versus right
significant differences in the SFE, emodin treatment reduces the SFE of the right 4T1
tumors but not the left 4T1 tumors. (D) Self-Renewal of left versus right DMSO and
Emodin treated 4T1 cancer stem-like cells shows the base line left versus right differences
and no effect by emodin treatment (* p<0.05) (** p<0.01).
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Chapter 5
Conclusion and Future Perspective
The proposed seed and soil hypothesis has significantly increased our current
understanding of the role of cancer cells “seed” and the microenvironment “soil” in
metastasis (140, 185). However, metastatic development is still the main cause of breast
cancer mortality. That is in part because studies have been focusing only on the role of
the stroma (19, 185, 186), and ignoring the other component of the mammary
microenvironment, the epithelium. Failure to consider the role of the epithelial
microenvironment may be a significant limitation in understanding and identifying
metastatic regulators. This limitation is due the use of orthotopic mouse models in which
tumor cells are incubated within the stromal microenvironment (fat pad), altogether
bypassing the epithelium. Thus, the first aim of this study was to overcome this limitation
by considering the role of the epithelium in breast cancer progression and metastasis
using 4T1 mouse model.
By using the intraductal injection, we were able to consider the role of the
epithelium in 4T1 tumor progression and metastasis. Our results, chapter 2, confirmed
that the epithelial microenvironment supports more aggressive 4T1 tumors compared to
4T1 tumors generated within the stroma. Our result showed that including the epithelial
microenvironment causes changes in 4T1 tumor properties, including: faster growth rate,

86

more aggressive histopathology, and earlier metastatic development, compared to 4T1
fat pad generated tumors. Moreover, RNA-sequencing analysis revealed molecular
changes in 4T1 cells after intraductal incubation when compared to non-injected 4T1
cells. Furthermore, the RNA-Sequencing analysis identified multiple pathways that are
associated with more aggressive 4T1 cells and have not been reported in 4T1 fat pad
generated tumors. Together, these results show the epithelial microenvironment’s ability
to support more aggressive 4T1 tumors compared to the stromal microenvironment
which will open up new avenues in studying metastatic regulators.
Another unappreciated factor that might limit our understanding of metastatic
regulators is the tumor situs. Mammary glands develop as paired organs, and it has been
demonstrated that left and right mammary glands exhibit different molecular profiles
(92). Moreover, some of left versus right differentially expressed genes are associated
with tumorigenesis and therapeutic response (92). Furthermore, epidemiological studies
have shown left-right difference in tumor aggressiveness and patients’ survival rate (90,
93, 187). These findings suggest that there may be left-right differences in tumor biology
which further suggest that there are differences in left versus right microenvironmental
support of tumorigenesis. Therefore, we investigated if left versus right mammary
microenvironments differentially support tumor progression and metastasis.
Our results, chapter 3, demonstrated for the first time that left versus right
mammary microenvironments form 4T1 tumors with different properties including:
tumor histopathology, 4T1 gene expression, macrophage polarization, and metastatic
behavior. The right mammary microenvironment promotes more advanced 4T1 tumor
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histopathology with greater muscle invasion and collagen deposition compared to the left
microenvironment. Our results also revealed the right microenvironment’s ability to alter
4T1 gene expression. RNA-Sequencing analysis showed that the genes that are upregulated in 4T1 cells isolated from right tumors are associated with more aggressive
disease progression such as MMPs, Wnt, and several genes from the COL and Hox families
(68, 132, 156, 163). In 4T1 cells isolated from left tumors, upregulated genes are
associated with enhanced anti-tumor immunity, such as CCL12, CXCL13, and CD226(164166). These results indicate the role of left versus right mammary microenvironments in
engineering cancer cells which then impact their metastatic activity. Moreover, TAMs
polarization was different in left versus right tumors. While the total TAMs number was
the same in left and right microenvironments, the right tumors had a greater percentage
of M2 TAMs. Furthermore, our results showed that 4T1 tumors generated in the right
microenvironment have greater metastatic incidence and more lung lesions.
Taken together, our results in chapter 3 showed for the first time that the right
mammary microenvironment promotes more M2 tumor-associated macrophages which
promote more aggressive 4T1 cells and increased metastatic behavior. These results
indicate the importance of tumor situs in tumor progression and metastasis not only in
the perspective of mouse models but also in clinical analysis of breast cancer patients.
Thus, considering tumor situs when studying breast cancer will uncover unappreciated,
molecular and/ or cellular, changes that contribute to metastatic development.
Our results for left-right differences in the microenvironmental support of cancer
cells suggest left-right differences in therapeutic response. Our results showed that the
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right microenvironment promotes more M2 TAMs compare to left microenvironment.
This result lends support to the hypothesis that left-right mammary microenvironments
can respond differently to emodin treatment. Emodin is the active ingredient of several
Chinese herbs and has been used for a long time to treat inflammatory disease (74).
Emodin has furthermore been found to have anti-cancer properties, which makes it a
potential cancer therapy. Emodin toxicity towards cancer cells is accomplished through
targeting different signaling pathways such as NFκB, ERK 1/2, p38, JUNK and PI3K/AKT in
different cell lines(78). Moreover, studies have reported that emodin can effect tumor
microenvironment and inhibit tumor growth and metastasis through its effect on TAMs
polarization and M2 TAMs recruitment to the lung (77, 84, 85).
Our results, chapter 4, indicated for the first time that left and right mammary
tumors have a different therapeutic response to emodin. Emodin inhibits lung metastasis
incidence and burden in mice bearing right side 4T1 tumors, while having no effect on
mice bearing left 4T1 tumors. Our results showed that emodin also reduces the total
number of TAMs in right tumors. Moreover, our PCR results showed that emodin
treatment reduces M2 TAMs in right 4T1 tumors. Furthermore, emodin treatment was
able to reduce cancer stem cells population in right 4T1 tumors. These results indicate
that emodin treatments inhibits the support of the right microenvironment to metastatic
activity and this inhibition is modulated through targeting TAMs, ultimately effecting the
CSCs population.
Our results demonstrated for the first time that left and right mammary
microenvironments differentially support tumor progression, metastasis, and therapeutic
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response. This indicates the importance of considering tumor laterality in the study of
breast cancer not only in preclinical mouse models but also in patients’ data analysis.
Laterality could be used as a tool to further understand metastatic regulators in breast
cancer. More studies are needed to further understand the mechanism by which the right
mammary microenvironment supports the growth of more aggressive tumors.
Furthermore, the data presented in this project indicates the importance of laterality to
be studied in other cancers that originate in paired organs.
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